CA2281956C - A novel protease - Google Patents
A novel protease Download PDFInfo
- Publication number
- CA2281956C CA2281956C CA002281956A CA2281956A CA2281956C CA 2281956 C CA2281956 C CA 2281956C CA 002281956 A CA002281956 A CA 002281956A CA 2281956 A CA2281956 A CA 2281956A CA 2281956 C CA2281956 C CA 2281956C
- Authority
- CA
- Canada
- Prior art keywords
- dna
- protease
- sequence
- seq
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108091005804 Peptidases Proteins 0.000 title claims abstract description 41
- 239000004365 Protease Substances 0.000 title claims abstract description 41
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title claims abstract 12
- 241000194108 Bacillus licheniformis Species 0.000 claims abstract description 26
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 16
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims abstract description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 11
- 229920001184 polypeptide Polymers 0.000 claims abstract description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 69
- 230000002255 enzymatic effect Effects 0.000 claims description 16
- 150000001413 amino acids Chemical group 0.000 claims description 14
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 claims description 6
- 229960005051 fluostigmine Drugs 0.000 claims description 6
- 108010022999 Serine Proteases Proteins 0.000 claims description 3
- 102000012479 Serine Proteases Human genes 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 36
- 108020004414 DNA Proteins 0.000 description 112
- 239000012634 fragment Substances 0.000 description 75
- 102000004190 Enzymes Human genes 0.000 description 55
- 108090000790 Enzymes Proteins 0.000 description 55
- 238000000034 method Methods 0.000 description 48
- 239000013615 primer Substances 0.000 description 40
- 239000002987 primer (paints) Substances 0.000 description 40
- 108700040178 Bacillus licheniformis blaSE Proteins 0.000 description 39
- 208000002352 blister Diseases 0.000 description 38
- 239000002585 base Substances 0.000 description 30
- 102000035195 Peptidases Human genes 0.000 description 29
- 235000019419 proteases Nutrition 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 150000007523 nucleic acids Chemical group 0.000 description 20
- 230000000692 anti-sense effect Effects 0.000 description 18
- 239000013604 expression vector Substances 0.000 description 17
- 235000014469 Bacillus subtilis Nutrition 0.000 description 15
- 238000003776 cleavage reaction Methods 0.000 description 15
- 230000007017 scission Effects 0.000 description 15
- 244000063299 Bacillus subtilis Species 0.000 description 14
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 13
- 239000001110 calcium chloride Substances 0.000 description 13
- 229910001628 calcium chloride Inorganic materials 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 108091005658 Basic proteases Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 239000013605 shuttle vector Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 108020004682 Single-Stranded DNA Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 238000000246 agarose gel electrophoresis Methods 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical group NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 5
- 239000003155 DNA primer Substances 0.000 description 5
- 238000010222 PCR analysis Methods 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 235000004400 serine Nutrition 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- MHHUEAIBJZWDBH-YUMQZZPRSA-N Gly-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN MHHUEAIBJZWDBH-YUMQZZPRSA-N 0.000 description 4
- LYZYGGWCBLBDMC-QWHCGFSZSA-N Gly-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CN)C(=O)O LYZYGGWCBLBDMC-QWHCGFSZSA-N 0.000 description 4
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 235000004554 glutamine Nutrition 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108010029020 prolylglycine Proteins 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- RRONHWAVOYADJL-HNNXBMFYSA-N (2s)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 RRONHWAVOYADJL-HNNXBMFYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108010020532 tyrosyl-proline Proteins 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101710105693 D-alanyl-D-alanine carboxypeptidase DacA Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AKOYRLRUFBZOSP-BJDJZHNGSA-N Ile-Lys-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N AKOYRLRUFBZOSP-BJDJZHNGSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 2
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 2
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- DGDCHPCRMWEOJR-FQPOAREZSA-N Thr-Ala-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DGDCHPCRMWEOJR-FQPOAREZSA-N 0.000 description 2
- PQLXHSACXPGWPD-GSSVUCPTSA-N Thr-Asn-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PQLXHSACXPGWPD-GSSVUCPTSA-N 0.000 description 2
- FASACHWGQBNSRO-ZEWNOJEFSA-N Tyr-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FASACHWGQBNSRO-ZEWNOJEFSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 2
- 108010087823 glycyltyrosine Proteins 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000036647 reaction Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HMRWQTHUDVXMGH-GUBZILKMSA-N Ala-Glu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HMRWQTHUDVXMGH-GUBZILKMSA-N 0.000 description 1
- LNNSWWRRYJLGNI-NAKRPEOUSA-N Ala-Ile-Val Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O LNNSWWRRYJLGNI-NAKRPEOUSA-N 0.000 description 1
- QUIGLPSHIFPEOV-CIUDSAMLSA-N Ala-Lys-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O QUIGLPSHIFPEOV-CIUDSAMLSA-N 0.000 description 1
- IETUUAHKCHOQHP-KZVJFYERSA-N Ala-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(O)=O IETUUAHKCHOQHP-KZVJFYERSA-N 0.000 description 1
- CLOMBHBBUKAUBP-LSJOCFKGSA-N Ala-Val-His Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N CLOMBHBBUKAUBP-LSJOCFKGSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- PEFFAAKJGBZBKL-NAKRPEOUSA-N Arg-Ala-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O PEFFAAKJGBZBKL-NAKRPEOUSA-N 0.000 description 1
- NONSEUUPKITYQT-BQBZGAKWSA-N Arg-Asn-Gly Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N)CN=C(N)N NONSEUUPKITYQT-BQBZGAKWSA-N 0.000 description 1
- AIFHRTPABBBHKU-RCWTZXSCSA-N Arg-Thr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AIFHRTPABBBHKU-RCWTZXSCSA-N 0.000 description 1
- GFFRWIJAFFMQGM-NUMRIWBASA-N Asn-Glu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GFFRWIJAFFMQGM-NUMRIWBASA-N 0.000 description 1
- SKQTXVZTCGSRJS-SRVKXCTJSA-N Asn-Tyr-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O SKQTXVZTCGSRJS-SRVKXCTJSA-N 0.000 description 1
- UGKZHCBLMLSANF-CIUDSAMLSA-N Asp-Asn-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UGKZHCBLMLSANF-CIUDSAMLSA-N 0.000 description 1
- UFAQGGZUXVLONR-AVGNSLFASA-N Asp-Gln-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N)O UFAQGGZUXVLONR-AVGNSLFASA-N 0.000 description 1
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 description 1
- FAUPLTGRUBTXNU-FXQIFTODSA-N Asp-Pro-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O FAUPLTGRUBTXNU-FXQIFTODSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005572 Cathepsin A Human genes 0.000 description 1
- 108010059081 Cathepsin A Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- GGRDJANMZPGMNS-CIUDSAMLSA-N Cys-Ser-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O GGRDJANMZPGMNS-CIUDSAMLSA-N 0.000 description 1
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 description 1
- WTJIWXMJESRHMM-XDTLVQLUSA-N Gln-Tyr-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O WTJIWXMJESRHMM-XDTLVQLUSA-N 0.000 description 1
- WPLGNDORMXTMQS-FXQIFTODSA-N Glu-Gln-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O WPLGNDORMXTMQS-FXQIFTODSA-N 0.000 description 1
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 1
- FVGOGEGGQLNZGH-DZKIICNBSA-N Glu-Val-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FVGOGEGGQLNZGH-DZKIICNBSA-N 0.000 description 1
- FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 1
- QPTNELDXWKRIFX-YFKPBYRVSA-N Gly-Gly-Gln Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O QPTNELDXWKRIFX-YFKPBYRVSA-N 0.000 description 1
- HAXARWKYFIIHKD-ZKWXMUAHSA-N Gly-Ile-Ser Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HAXARWKYFIIHKD-ZKWXMUAHSA-N 0.000 description 1
- LRQXRHGQEVWGPV-NHCYSSNCSA-N Gly-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN LRQXRHGQEVWGPV-NHCYSSNCSA-N 0.000 description 1
- AFWYPMDMDYCKMD-KBPBESRZSA-N Gly-Leu-Tyr Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFWYPMDMDYCKMD-KBPBESRZSA-N 0.000 description 1
- GAAHQHNCMIAYEX-UWVGGRQHSA-N Gly-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GAAHQHNCMIAYEX-UWVGGRQHSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- YXTFLTJYLIAZQG-FJXKBIBVSA-N Gly-Thr-Arg Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YXTFLTJYLIAZQG-FJXKBIBVSA-N 0.000 description 1
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 1
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- BQYZXYCEKYJKAM-VGDYDELISA-N His-Cys-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQYZXYCEKYJKAM-VGDYDELISA-N 0.000 description 1
- ZVKDCQVQTGYBQT-LSJOCFKGSA-N His-Pro-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O ZVKDCQVQTGYBQT-LSJOCFKGSA-N 0.000 description 1
- UPJODPVSKKWGDQ-KLHWPWHYSA-N His-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)O UPJODPVSKKWGDQ-KLHWPWHYSA-N 0.000 description 1
- QICVAHODWHIWIS-HTFCKZLJSA-N Ile-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N QICVAHODWHIWIS-HTFCKZLJSA-N 0.000 description 1
- LPXHYGGZJOCAFR-MNXVOIDGSA-N Ile-Glu-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N LPXHYGGZJOCAFR-MNXVOIDGSA-N 0.000 description 1
- SLQVFYWBGNNOTK-BYULHYEWSA-N Ile-Gly-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N SLQVFYWBGNNOTK-BYULHYEWSA-N 0.000 description 1
- LBRCLQMZAHRTLV-ZKWXMUAHSA-N Ile-Gly-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LBRCLQMZAHRTLV-ZKWXMUAHSA-N 0.000 description 1
- QGXQHJQPAPMACW-PPCPHDFISA-N Ile-Thr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QGXQHJQPAPMACW-PPCPHDFISA-N 0.000 description 1
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- QPXBPQUGXHURGP-UWVGGRQHSA-N Leu-Gly-Met Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)O)N QPXBPQUGXHURGP-UWVGGRQHSA-N 0.000 description 1
- LIINDKYIGYTDLG-PPCPHDFISA-N Leu-Ile-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LIINDKYIGYTDLG-PPCPHDFISA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- GAOJCVKPIGHTGO-UWVGGRQHSA-N Lys-Arg-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O GAOJCVKPIGHTGO-UWVGGRQHSA-N 0.000 description 1
- DGWXCIORNLWGGG-CIUDSAMLSA-N Lys-Asn-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O DGWXCIORNLWGGG-CIUDSAMLSA-N 0.000 description 1
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 1
- WZVSHTFTCYOFPL-GARJFASQSA-N Lys-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N)C(=O)O WZVSHTFTCYOFPL-GARJFASQSA-N 0.000 description 1
- MEQLGHAMAUPOSJ-DCAQKATOSA-N Lys-Ser-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O MEQLGHAMAUPOSJ-DCAQKATOSA-N 0.000 description 1
- PLOUVAYOMTYJRG-JXUBOQSCSA-N Lys-Thr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PLOUVAYOMTYJRG-JXUBOQSCSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- MCNGIXXCMJAURZ-VEVYYDQMSA-N Met-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)N)O MCNGIXXCMJAURZ-VEVYYDQMSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- BSKMOCNNLNDIMU-CDMKHQONSA-N Phe-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O BSKMOCNNLNDIMU-CDMKHQONSA-N 0.000 description 1
- ULIWFCCJIOEHMU-BQBZGAKWSA-N Pro-Gly-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 ULIWFCCJIOEHMU-BQBZGAKWSA-N 0.000 description 1
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- LZHHZYDPMZEMRX-STQMWFEESA-N Pro-Tyr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O LZHHZYDPMZEMRX-STQMWFEESA-N 0.000 description 1
- VEUACYMXJKXALX-IHRRRGAJSA-N Pro-Tyr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VEUACYMXJKXALX-IHRRRGAJSA-N 0.000 description 1
- VDHGTOHMHHQSKG-JYJNAYRXSA-N Pro-Val-Phe Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O VDHGTOHMHHQSKG-JYJNAYRXSA-N 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 101710132632 Protein C4 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MESDJCNHLZBMEP-ZLUOBGJFSA-N Ser-Asp-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MESDJCNHLZBMEP-ZLUOBGJFSA-N 0.000 description 1
- UFKPDBLKLOBMRH-XHNCKOQMSA-N Ser-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N)C(=O)O UFKPDBLKLOBMRH-XHNCKOQMSA-N 0.000 description 1
- GZBKRJVCRMZAST-XKBZYTNZSA-N Ser-Glu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZBKRJVCRMZAST-XKBZYTNZSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 1
- IXZHZUGGKLRHJD-DCAQKATOSA-N Ser-Leu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IXZHZUGGKLRHJD-DCAQKATOSA-N 0.000 description 1
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 1
- NQZFFLBPNDLTPO-DLOVCJGASA-N Ser-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CO)N NQZFFLBPNDLTPO-DLOVCJGASA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- VASYSJHSMSBTDU-LKXGYXEUSA-N Thr-Asn-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N)O VASYSJHSMSBTDU-LKXGYXEUSA-N 0.000 description 1
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 1
- VBPDMBAFBRDZSK-HOUAVDHOSA-N Thr-Asn-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O VBPDMBAFBRDZSK-HOUAVDHOSA-N 0.000 description 1
- MPUMPERGHHJGRP-WEDXCCLWSA-N Thr-Gly-Lys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O MPUMPERGHHJGRP-WEDXCCLWSA-N 0.000 description 1
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 1
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 1
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- AKHDFZHUPGVFEJ-YEPSODPASA-N Thr-Val-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AKHDFZHUPGVFEJ-YEPSODPASA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- TWJDQTTXXZDJKV-BPUTZDHNSA-N Trp-Arg-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O TWJDQTTXXZDJKV-BPUTZDHNSA-N 0.000 description 1
- CPZTZWFFGVKHEA-SZMVWBNQSA-N Trp-Gln-His Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)N CPZTZWFFGVKHEA-SZMVWBNQSA-N 0.000 description 1
- RIKLKPANMFNREP-FDARSICLSA-N Trp-Met-Ile Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)=CNC2=C1 RIKLKPANMFNREP-FDARSICLSA-N 0.000 description 1
- CKKFTIQYURNSEI-IHRRRGAJSA-N Tyr-Asn-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CKKFTIQYURNSEI-IHRRRGAJSA-N 0.000 description 1
- MNMYOSZWCKYEDI-JRQIVUDYSA-N Tyr-Asp-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MNMYOSZWCKYEDI-JRQIVUDYSA-N 0.000 description 1
- CNLKDWSAORJEMW-KWQFWETISA-N Tyr-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O CNLKDWSAORJEMW-KWQFWETISA-N 0.000 description 1
- JAGGEZACYAAMIL-CQDKDKBSSA-N Tyr-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)N JAGGEZACYAAMIL-CQDKDKBSSA-N 0.000 description 1
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 description 1
- OKDNSNWJEXAMSU-IRXDYDNUSA-N Tyr-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 OKDNSNWJEXAMSU-IRXDYDNUSA-N 0.000 description 1
- VPEFOFYNHBWFNQ-UFYCRDLUSA-N Tyr-Pro-Tyr Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 VPEFOFYNHBWFNQ-UFYCRDLUSA-N 0.000 description 1
- MDXLPNRXCFOBTL-BZSNNMDCSA-N Tyr-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MDXLPNRXCFOBTL-BZSNNMDCSA-N 0.000 description 1
- DLMNFMXSNGTSNJ-PYJNHQTQSA-N Val-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C(C)C)N DLMNFMXSNGTSNJ-PYJNHQTQSA-N 0.000 description 1
- UKEVLVBHRKWECS-LSJOCFKGSA-N Val-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)N UKEVLVBHRKWECS-LSJOCFKGSA-N 0.000 description 1
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- YLBNZCJFSVJDRJ-KJEVXHAQSA-N Val-Thr-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O YLBNZCJFSVJDRJ-KJEVXHAQSA-N 0.000 description 1
- GUIYPEKUEMQBIK-JSGCOSHPSA-N Val-Tyr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(O)=O GUIYPEKUEMQBIK-JSGCOSHPSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010045023 alanyl-prolyl-tyrosine Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010090037 glycyl-alanyl-isoleucine Proteins 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010074027 glycyl-seryl-phenylalanine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010084389 glycyltryptophan Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 108010007375 seryl-seryl-seryl-arginine Proteins 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pretreatment Of Seeds And Plants (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
A novel protease derived from Bacillus licheniformis is provided. The protease cleaves the peptide bonds at the carboxyl termini of glutamic acid residues in polypeptides. The protease contains an amino acid sequence from serine in the +1 position to glutamine in the +222 position of SEQ ID NO: 1.
Description
This application is a divisional of Canadian Patent Application Serial No. 2,054,030 filed on October 23, 1991 wherein the invention of the present application is directed to a novel protease. In order to assist in a ready under-standing of the overall invention, all features of the inventive concept, the teachings of those features and the broad objects relating thereto, are all retained in the present description as they were in the description of the aforementioned parent application.
Accordingly, the present invention relates to a novel protease which specifically cleaves the peptide bond at the carboxyl termini of glutamic acid residues in the amino acid sequences of polypeptides, a method for producing the protease from bacteria of the genus Bacillus, a DNA sequence encoding the protease, an expression vector containing the DNA sequence, a transformant obtained by introducing this expression vector into a host, and a method for producing the protease using the transformant.
The V8 protease derived from the V8 strain of Staphylococcus aureus is already known as an enzyme which acts upon proteins (i.e., polypeptides) and specifically cleaves the peptide bond at the carboxyl terminal of glutamic acid (Glu) residues (Gabriel R. Drapeau et al., J. Biol.
Chem. 247, 20, 6720-6726, 1972). This enzyme is classified as a serine protease. C. Carmona et al. have cloned the DNA
sequence encoding this enzyme (Nucl. Acids Res., 15, 6757, 1987) .
A similar enzyme, an endopetidase which is specific for acidic amino acid residue and is derived from an actinomycete bacterium Streptomyces griseus, is also known (Norio Yoshida et al., J. Biochem. 104, 3, 451-456, 1988).
Furthermore, an endoprotease which is specific for glutamic acid residue derived from Bacillus subtilis is also known (Takuro Niidome, Norio Yoshida, Fusahiro Ogata, Akio Ito, and Kosaku Noda, J. Biochem. 108, 965-970, 1990); Abstracts of 62nd General Conference of the Japan Biochemical Society).
Accordingly, the present invention relates to a novel protease which specifically cleaves the peptide bond at the carboxyl termini of glutamic acid residues in the amino acid sequences of polypeptides, a method for producing the protease from bacteria of the genus Bacillus, a DNA sequence encoding the protease, an expression vector containing the DNA sequence, a transformant obtained by introducing this expression vector into a host, and a method for producing the protease using the transformant.
The V8 protease derived from the V8 strain of Staphylococcus aureus is already known as an enzyme which acts upon proteins (i.e., polypeptides) and specifically cleaves the peptide bond at the carboxyl terminal of glutamic acid (Glu) residues (Gabriel R. Drapeau et al., J. Biol.
Chem. 247, 20, 6720-6726, 1972). This enzyme is classified as a serine protease. C. Carmona et al. have cloned the DNA
sequence encoding this enzyme (Nucl. Acids Res., 15, 6757, 1987) .
A similar enzyme, an endopetidase which is specific for acidic amino acid residue and is derived from an actinomycete bacterium Streptomyces griseus, is also known (Norio Yoshida et al., J. Biochem. 104, 3, 451-456, 1988).
Furthermore, an endoprotease which is specific for glutamic acid residue derived from Bacillus subtilis is also known (Takuro Niidome, Norio Yoshida, Fusahiro Ogata, Akio Ito, and Kosaku Noda, J. Biochem. 108, 965-970, 1990); Abstracts of 62nd General Conference of the Japan Biochemical Society).
The aforesaid enzymes are useful when specific cleavage of proteins at the aforesaid sites is desired for the purposes of protein structural analysis, etc., or when recombinant DNA techniques have been employed to produce a desired protein in the form of a certain fusion protein, from which the desired protein is to be obtained by cleavage. In the latter case, for example, when the desired protein has been produced in the form of a fusion protein in which the desired protein is linked with another protein via a glutamic acid residue, the desired protein can be separated by cleavage with such an enzyme. For these reasons, the availability of other proteases possessing this type of enzymatic activity, in addition to those mentioned above, would be highly desirable.
The novel protease of this invention, which overcomes the above-discussed and numerous other disadvantages and deficiencies of the prior art, is derived from Bacillus licheniformis.
Therefore, according to the present invention, there is provided a purified and isolated protease, which cleaves the peptide bonds at the carboxyl termini of glutamic acid residues in polypeptides, and which contains an amino acid sequence from serine in the +1 position to glutamine in the +222 position of SEQ ID NO. 1.
In a preferred embodiment, the protease is derived from Bacillus licheniformis ATCC No. 14580.
The novel protease of this invention, which overcomes the above-discussed and numerous other disadvantages and deficiencies of the prior art, is derived from Bacillus licheniformis.
Therefore, according to the present invention, there is provided a purified and isolated protease, which cleaves the peptide bonds at the carboxyl termini of glutamic acid residues in polypeptides, and which contains an amino acid sequence from serine in the +1 position to glutamine in the +222 position of SEQ ID NO. 1.
In a preferred embodiment, the protease is derived from Bacillus licheniformis ATCC No. 14580.
In a preferred embodiment, the protease has the following properties:
(1) Optimal pH: approximately 8.0, and (2) Stable pH range: pH 6.5-8.5 at 25°C.
In a preferred embodiment, the protease contains an amino acid sequence from serine in the +1 position to glutamirie in the +222 position of SEQ ID NO: 1, and cleaves the peptide bonds at the carboxyl termini of glutamic acid residues in polypeptides.
The DNA sequence of this invention encodes the above-mentioned protease.
In a preferred embodiment, the DNA sequence contains a base sequence from the thymine residue in the 605 position to the adenosine residue in the 1270 position of SEQ ID NO: 1.
In a preferred embodiment, the DNA sequence encodes a protease containing an amino acid sequence from N-formylmethionine at the -94 position to the glutamine at the +222 position of SEQ ID NO: 1.
In a preferred embodiment, the DNA sequence contains a base sequence, from the thymine residue in the 323 position to the adenosine residue in the 1270 position, of SEQ ID NO:
1.
(1) Optimal pH: approximately 8.0, and (2) Stable pH range: pH 6.5-8.5 at 25°C.
In a preferred embodiment, the protease contains an amino acid sequence from serine in the +1 position to glutamirie in the +222 position of SEQ ID NO: 1, and cleaves the peptide bonds at the carboxyl termini of glutamic acid residues in polypeptides.
The DNA sequence of this invention encodes the above-mentioned protease.
In a preferred embodiment, the DNA sequence contains a base sequence from the thymine residue in the 605 position to the adenosine residue in the 1270 position of SEQ ID NO: 1.
In a preferred embodiment, the DNA sequence encodes a protease containing an amino acid sequence from N-formylmethionine at the -94 position to the glutamine at the +222 position of SEQ ID NO: 1.
In a preferred embodiment, the DNA sequence contains a base sequence, from the thymine residue in the 323 position to the adenosine residue in the 1270 position, of SEQ ID NO:
1.
The expression vector of this invention contains the above-mentioned DNA sequence.
In a preferred embodiment, the expression vector is expressible in bacteria of the genus Bacil lus.
The transformant of this invention is obtain able by introducing the above-mentioned expression vector into a host.
In a preferred embodiment, the host is a strain belonging to the genus Bacillus.
The method for producing a protease of this invention comprises the steps of cultivating a strain of Bacillus licheniformis capable of producing the above-mentioned protease in a culture medium and recovering the produced protease from the culture medium.
The method for producing a protease of this invention comprises the steps of cultivating the above-mentioned transformant in a culture medium and recovering the produced protease from the culture medium.
It is understood that various other modifica-tions will be apparent to and can be readily made by those skilled in the art without departing from the scope and spirit of this invention. Accordingly, it is not intended that the scope of the claims appended hereto be limited to the description as set forth herein, but rather that the claims be construed as encompassing all the features of patentable novelty that reside in-the present invention, including all features that would be treated as equivalents thereof by those skilled in the art to which this invention pertains.
Thus, the invention described herein makes possible the objective of providing a novel protease with an enzymatic activity of specifically cleaving polypeptides at the carboxyl termini of glutamic acid residues.
Accordingly, the invention provides for a purified and isolated protease, which cleaves the peptide bonds at the carboxyl termini of glutamic acid residues in polypeptides, and which contains an amino acid sequence from serine in the +1 position to glutamine in the +222 position of SEQ ID NO:
1.
This invention may be better understood and its numerous objects and advantages will become apparent to those skilled in the art by reference to the accompanying drawings as follows:
Figures 1-1 to 1-3 show the DNA sequence of the protease of the present invention and the amino acid sequence deduced from the DNA sequence.
Figure 2 a.s a schematic diagram illustrating the construction of the expression vector pHY300BLtt of the present invention.
Figure 3 is a schematic diagram illustrating the construction of the shuttle vector pHY300PLKtt used in the construction of the expression vector pHY300BLtt of the present invention.
Figure 4 shows graphs indicating the elution of the enzyme of the present invention from an affinity column in the process of extraction and purification of the enzyme from the medium in which Bacillus licheni-formis ATCC No. 14580 was cultivated.
The present inventors have conducted various studies with a view to obtaining prbteases, possessing the enzymatic action of cleaving peptides at the car-boxyl termini of glutamic acid residues, from micro-organisms other than the aforesaid Staphylococcus aureus, etc. As a result of these researches, the present inventors have discovered a novel protease possessing the aforesaid property, derived from Bacil-lus licheniformis ATCC No. 14580. Furthermore, the present~inventors have also found a DNA sequence encod-ing this protease and created an expression vector containing the DNA sequence as well as transformant obtained by introduction of the expression vector into a host, and discovered a method for the production of this protease using the transformant, thereby complet-ing the present invention.
In a preferred embodiment, the expression vector is expressible in bacteria of the genus Bacil lus.
The transformant of this invention is obtain able by introducing the above-mentioned expression vector into a host.
In a preferred embodiment, the host is a strain belonging to the genus Bacillus.
The method for producing a protease of this invention comprises the steps of cultivating a strain of Bacillus licheniformis capable of producing the above-mentioned protease in a culture medium and recovering the produced protease from the culture medium.
The method for producing a protease of this invention comprises the steps of cultivating the above-mentioned transformant in a culture medium and recovering the produced protease from the culture medium.
It is understood that various other modifica-tions will be apparent to and can be readily made by those skilled in the art without departing from the scope and spirit of this invention. Accordingly, it is not intended that the scope of the claims appended hereto be limited to the description as set forth herein, but rather that the claims be construed as encompassing all the features of patentable novelty that reside in-the present invention, including all features that would be treated as equivalents thereof by those skilled in the art to which this invention pertains.
Thus, the invention described herein makes possible the objective of providing a novel protease with an enzymatic activity of specifically cleaving polypeptides at the carboxyl termini of glutamic acid residues.
Accordingly, the invention provides for a purified and isolated protease, which cleaves the peptide bonds at the carboxyl termini of glutamic acid residues in polypeptides, and which contains an amino acid sequence from serine in the +1 position to glutamine in the +222 position of SEQ ID NO:
1.
This invention may be better understood and its numerous objects and advantages will become apparent to those skilled in the art by reference to the accompanying drawings as follows:
Figures 1-1 to 1-3 show the DNA sequence of the protease of the present invention and the amino acid sequence deduced from the DNA sequence.
Figure 2 a.s a schematic diagram illustrating the construction of the expression vector pHY300BLtt of the present invention.
Figure 3 is a schematic diagram illustrating the construction of the shuttle vector pHY300PLKtt used in the construction of the expression vector pHY300BLtt of the present invention.
Figure 4 shows graphs indicating the elution of the enzyme of the present invention from an affinity column in the process of extraction and purification of the enzyme from the medium in which Bacillus licheni-formis ATCC No. 14580 was cultivated.
The present inventors have conducted various studies with a view to obtaining prbteases, possessing the enzymatic action of cleaving peptides at the car-boxyl termini of glutamic acid residues, from micro-organisms other than the aforesaid Staphylococcus aureus, etc. As a result of these researches, the present inventors have discovered a novel protease possessing the aforesaid property, derived from Bacil-lus licheniformis ATCC No. 14580. Furthermore, the present~inventors have also found a DNA sequence encod-ing this protease and created an expression vector containing the DNA sequence as well as transformant obtained by introduction of the expression vector into a host, and discovered a method for the production of this protease using the transformant, thereby complet-ing the present invention.
The protease of the present invention (here-inafter referred to as BLase) is produced by bacteria of the genus Bacillus, in particular, by Bacillus licheniformis ATCC No. 14580. This strain is available ~5 from the American Type Culture Collection (ATCC).
I. Culture conditions No special medium is required for the culti vation of the aforesaid bacterial strain, and any of the various conventional types of culture medium are suitable for this purpose. For example, a medium con-taining glucose, soybean powder, meat extract, corn steep liquor, and the various inorganic salts, etc., can be used. The appropriate medium pH is 5-9, prefer-ably approximately 7.0, the appropriate medium tempera-ture is 15-50°C, preferably approximately 28°C, and the bacteria are cultured, for example, aerobically with stirring or shaking for approximately 36 hours. The enzyme BLase of the present invention was principally secreted extracellularly.
II. Collection of enzyme Known processes for the collection and puri fication of enzymes can be used, either singly or in combination, for the collection and purification of the present enzyme from the aforesaid culture broth. For example, the culture broth can be subjected to filter pressing, ultrafiltration, and centrifugal separation, thereby obtaining a cell-free liquid concentrate. The enzyme of the present invention can then be obtained from this concentrate by an appropriate method of purification. For example, the aforesaid concentrate can be subjected first to preliminary purification by - g -ion exchange chromatography, and then to chromatography with S-Sepharose, and finally to affinity chromato-graphy, thereby obtaining the present enzyme. In Example 1 shown below, enzyme specimen with activity 1.9 x 103 to 2.4 x 103 U/mg (assayed by the method for the measurement of enzymatic activity described below) was obtained by this type of procedure. This enzyme specimen was used for the determination of enzyme properties described below.
III. Method for the measurement of enzymatic activity Z-Phe Leu Glu-pNA (wherein Z is a carbo-benzoxy group and pNA is a p-nitroaniline group), used as a substrate, is dissolved in 50 mM Tris-HC1 (pH 7.5, containing 2 mM calcium chloride and 2$ DMF) so as to achieve a final substrate concentration of 0.2 mM. An enzyme solution is added to this mixture, and a reac-tion is conducted at 37°C for 10 minutes, then the 410 nm absorbance of the p-nitroaniline released into the liquid by the enzymatic reaction is measured. The enzymatic activity present when this absorbance is 1.0 is defined as 1 unit (U).
IV. Enzyme properties The enzymatic properties and protein chemical properties of BLase of the present invention are as follows.
(1) Enzymatic action and substrate specificity (i) The synthetic substrates shows in Table 1 were prepared, and each of them was dissolved in 50 ml Tris-HC1 (pH 7.5, containing 2 mM calcium chloride and dimethylformamide (DMF) or dimethyl sulfoxide (DMSO) in _ g _ the proportions indicated by Table 1) so as to achieve the concentration shown in Table 1. Then, the present enzyme was added to this solution and a reaction was conducted at 25°C. The 410 nm absorbance of the p-nitroaniline released into the liquid by the enzyma-tic reaction was measured, and the quantity (nmol) of p-nitroaniline released from 1 mg of the substrate per minute was calculated; the results so obtained are shown in Table 1.
c .
. _.
c -- E
Q: c \
Ui c3 N O O O O O O O
C.C
e-~ C
E
CD G O O ' C O O O O
C
QJ . N
....
_ C E
I c I
Q.~' c p ~
~ t_ ~
-+~ O O O C J O 0 0 ( O
o~
cC '-~ N N .-~ .-.a,--1.--, .-v ~ L.
~~C
C C Vj Q: ~
U4-O p C O C -. L. LL '.-.L. Vj ',- C-O ~ ' ~ ~ ,.s ~
U ' p p D C~ C ~ C
s' C~
.~~
-~ E
c -s Q7 c~ L.'7 L~J
U t-. O O O O .-t -C' O O O
c .~.~
C cn O O N N O O ~-t --s C: ..O
c ci-.
. _. p + .~ a- + .r a. t .t .z.
d d d d d d -~ d d a:
z ~ ~. z z z z z a. c, c. .:. c, c. Q. :..,c.
a. _ Q .~ c. ~:..~, ~. ~ .
, _.
+= --r C!) ~- V; ~ ~.. ~; --~ Q: C
cts O d C~ d E- C C/: d .. c~
~
._.
-i' ~ - ~, c~ t-, U: C1: Q: :: ~,; N N -- ---~ _.. .._ -~ d CC C.~ CC d .
~ _.
--tC~: Q7 Q: ~ I
_ ~ ~ sw Ci ~ ~ Q
..D N N U -C
' C
i (ii) Oxidized insulin B chain was selected as a protein substrate, and the actions of the present enzyme and V8 protease derived from Staphylococcus aureus upon this substrate were compared by the follow-s ing procedure. First, oxidized insulin B chain was dissolved in 50 mM ammonium bicarbonate (pH 7.8), the present enzyme or the aforesaid V8 protease was added so as to achieve an enzyme/substrate ratio of 1/100 (W/W), and a reaction was conducted over a prescribed period of time. The reaction mixture was then sub-jected to HPLC using a 4.6 x 250 mm column packed with Vydac Protein C4 (300 angstroms), which was eluted under a 0-50~ acetonitrile linear gradient in 0.1$ TFA, raising the acetonitrile concentration by 1.67~/min.
Peptide mapping revealed that, when either of the enzymes was used, the peptide bonds at the carboxyl termini of the glutamic acid residues were cleaved, and the products of enzymatic hydrolysis induced by the two enzymes were identical with each other.
Thus, the results of the aforesaid analyses (i) and (ii) demonstrated that the present enzyme cleaves peptide bonds at the carboxyl termini of glu tamic acid residues, and is indeed a glutamic acid specific endopeptidase.
(2) Optimal pH and stable pH range Z-Phe Leu Glu-pNA as a substrate was dis solved in 50 mM Tris-HC1 containing 10$ DMF and 2 mM
calcium chloride. Then, the present enzyme was added to this mixture, a reaction was conducted for 15 minutes at 37°C, and the 410 nm absorbance of the p-nitroaniline released into the liquid by the enzymat-is reaction was measured. The aforesaid reaction was conducted at various pH values, and the results re-vealed that the optimal pH for enzymatic activity is 8Ø
Next, the present enzyme was maintained at 25°C for 24 hours at various pH values, and in each case the enzyme after this treatment was allowed to react with a substrate in accordance with the proce-dures described in the method for the measurement of enzymatic activity mentioned above. The results indi-cate that the stable pH range of the present enzyme is about 4.0-10Ø In a pH range of 6.5-8.5, the enzymat-ic activity is maintained at 100$, and in pH ranges ex-ceeding 4.0 up to less than 6.5, and exceeding 8.5 up to 10.0, the enzymatic activity is maintained at 80-100$.
(3) Thermal stability The present enzyme was maintained for 15 minutes at various temperatures in a buffer solution containing 2 mM calcium chloride at pH 7.8. In each case, the enzyme after this treatment was allowed to react with a substrate in accordance with the proce-dures described in the method for the measurement of enzymatic activity mentioned above. The results indicated that under the aforesaid conditions the present enzyme is stable at temperatures up to 60°C.
When the present enzyme was similarly kept in solutions not containing calcium chloride, it was stable at tem-peratures up to 50°C.
(4) Effect of inhibitors The present enzyme is completely inhibited by diisopropyl fluorophosphate (DFP). This fact indicates that the present enzyme is classified as a serine pro s tease.
The present enzyme is also completely inhib ited by Z-Phe Leu Glu CH2C1. This fact indicates that the present enzyme is a glutamic acid specific endo peptidase.
The present enzyme is partially inhibited by EDTA, with a maximum inhibition ratio of approximately 72$. This inhibitory effect of EDTA is completely nullified by the addition of metal ions at low concen-trations (10-4 to 10-3 M of calcium or magnesium ions, etc.).
The aforesaid facts indicate that the present enzyme is a typical serine protease, the stability of which is related to the presence of metal ions.
(5) Molecular weight The molecular weight of the present enzyme was determined by SDS-PAGE using 15$ gel (1.0 mm) and RainbowTM Protein Molecular Weight Marker (Amersham), and was calculated to be 26,000. The molecular weight was also calculated from the amino acid sequence deter mined on the basis of the gene sequencing analysis to be described below, and the value so obtained was 23,567 which is somewhat different from the aforesaid value obtained by SDS-PAGE. Nevertheless, the results of the various protein chemical analyses to be de-scribed below (amino acid composition, amino terminal sequences, amino acid composition in the vicinity of the carboxyl terminus) agreed well with the structure deduced from the DNA sequence. This indicates that the molecular weight obtained by SDS-PAGE was, in fact, slightly in excess of the true value.
(6) Isoelectric point Investigation of the isoelectric point of the present enzyme using the Pharmacia FAST System (Pharma lite, pH 3.0-10.0) yielded values above pH,9.0, and a normal value could not be obtained.
(7) Amino acid composition Using 4 M methanesulfonic acid (containing 0.2$ of 3-(2-aminoethyl)indole), the present enzyme was hydrolyzed at 110°C for prescribed time intervals (24, 48, or 72 hours). The respective hydrolysates were then subjected to amino acid analysis using a Hitachi Model 835 amino acid analyzer. The results of this analysis, corrected for the decomposition of amino acids in the process of hydrolysis, are shown in Table 2. The amino acid composition calculated from the DNA
sequence of the present enzyme (described below) are also shown for comparison in Table 2. The two sets of results clearly display good agreement.
cC C-Ir---41.C7CCD.---iCCDCv.~.L''COL~CCL'~OL~-> r-iC'~~."~L'7C'~'OOO~~O~G~7C0.'.VL~-~CO~G~
~O 0.~.Nr'C"~".'C"~JLOriLJJL~~7L'--CV:.Vr--~'C'r-1C7 N ,--a .--i ,.-.~ G~
c U
O
..-.. td .--' U
. r, O ' n E
O
U
U
..-. .-.
. r 00 ~ O7 G~ C r-1 ~G' Q~ 'J'J C~'J r---i U . ~''~ "~' L~- ~ C C'rJ r-I L~-c,~.
c~ ~ CJCO~'~C'L'CDCUGCCCCC~'JOC'rJL'L~-.---i~O
O 'C7 ~ ri cYJ L'J ~f' CYJ ttJ r-1 CD C O
CD G~l L'- CV ~7 .--1 '~ r-i C U '-1 r-I r-~ C
. .., E a d ~
U
.
r, U
C7 cd \
r--~ 0.. t. t-, ~ O ~ c~ CIA ,-.-~ .u U cd = t-, Q: C!i U7 CG G, ...CO Cn ..C N r--' t-, ,.- .- ~ c-,! Q: .~
~--~ U ~ .~ 7~ -- s~ L.
c-,-c.C d~--C/aC~~C~dU~~.--.fir-~.~sdE-- C
.
E
d (8) Partial amino acid sequences (i) Amino acid sequence near N terminus A Model 477A Protein Sequencer (Applied Biosystems) was used to analyze the amino acid sequence of the present enzyme in the vicinity of the amino terminus. The enzyme samples used were inhibited beforehand with DFP. The amino acid sequence from the amino terminus to the 23rd residue is shown in Table 3.
c~
.'.V ~J '~T~ L~J '~~~~ L~ r-1 per" 'C' 4'7 C-C a°
U ''-~ C' V O .-~ r--~ GV CV L''W'.V C'rJ 'C" C~l d7 L''~C''J~'JLt7CD'C'c'ri~GVG~7 G~
O 'n C ~ ~ G ~.. t-. cd ~. C 4.. C,p cL N ~
. .-. V V; ..c . ; ~--~ ~, t-. ~, t~ .-.-~ ,-.-.
E c~ d F- r- d E-- G.., E-. d d .-- ~
d C
O
cd Q
"',.~. G7 C'~J ~ LCD CD L~ x7 O~ O r--~ CV C~'J
cd .+~ r--~ r-~ ~ ~-i r-i r-~-i r-i ~ GV N N
by O
D
O
>~ r~CDCD~VCONr-iGYJoO:DCYJ'c'' O
U~ ~'Lt'Jr-SOC~7riy'Jr-I~LrJL'JCO
U CV o~ o~ ~ Gw7 l.n L~ Cf~ CrJ t-c~ :D ;'rJ
O "O
C ~ ~--~ t-, ,--~ QJ ~ L-. CL G. ta0 L-~ t~0 r-~ l-, ' ~' U d7 c~ .-. r-. N Cn (n L-. .G t-.. cd .C
~ cd c/~ ~- ~-~ C~ c/~ d d d E- d ~- E--d c O
. ....
U ~C U
cd .:._.y--( ~ C~r-r -c,'i L'~ C.O L~- 00 C3~ O ~--t '~7 f-. Cn r-i r-i r-1 c~ b0 U
C
(ii) Amino acid sequence near C terminus Carbvxypeptidase A (CPase A) or carboxypepti-dase Y (CPase Y) was allowed to act upon samples of the present enzyme inhibited beforehand with DFP, and the quantities of amino acids released by these reactions were measured with an amino acid analyzer of Hitachi Model 835. However, the amino acid sequence in the vicinity of the carboxyl terminus of the present enzyme could not be accurately determined using either of the aforesaid carboxypeptidases. Nevertheless, the presence of glutamine, serine, alanine and asparagine in the vicinity of the carboxyl terminus was verified.
V. Determination of DNA secruence encoding BLase Certain terminology employed in the specifi-cation of the present invention is defined as follows.
"Oligonucleotide" refers to a short single-strand DNA molecule. Oligonucleotides can be chemical-ly synthesized in accordance with known methods.
Unless otherwise stated, the oligonucleotides used in the processes of the present invention are chemically synthesized, and are purified by gel chromatography using Sephadex G50*and high-performance liquid chroma-tography (HPLC) with a reverse phase silica gel column.
"PCR" is an acronym of "polymerase chain reaction", and refers to a method for enzvmatic amDli-fication of a definite DNA region (Saiki et al., Science, 239, 487-497, 1988). First, the DNA to be amplified is converted to single-strand form by thermal denaturation, and oligonucleotide primers (two types, i.e., sense and antisense strands, each having a com-* trade-mark plemental sequence to the 3'-terminal region of the said single-stranded DNA) are annealed to the regions at the respective 3'-termini of the single-stranded DNA
(i.e., the template DNA). Next, the extension of the DNA strands from the respective primers is accomplished by a reaction using DNA polymerise. By repeating this sequence of reactions, the target DNA can be amplified by a factor of 100,000 to 1,000,000.
"Southern blotting" is a method for determin-ing whether or not a specified gene is contained in a DNA fragment obtained by cleavage with a certain re-striction enzyme. Southern blotting is performed by first digesting the DNA sample under investigation with a restriction enzyme which specifically recognizes a certain base sequence in duplex DNA and cleaves this DNA at specific sites. The digest so obtained is subjected to 1$ agarose gel electrophoresis, then denatured into single-stranded DNA by alkali treatment, and transferred to a nylon filter. Separately, an oligonucleotide or DNA fragment constituting a portion of the gene in question is prepared and labelled to obtain a probe. Hybridization of the single-stranded DNA on the nylon filter with this probe is then used to detect the presence of the gene in question.
"Ligation" refers to the creation of phospho-diester bond between two duplex DNA fragments. In this technique, in order to prevent the self-ligation of the duplex DNA fragments, one of the fragments is subjected to prior dephosphorylation treatment by the convention-al method (T. Maniatis et al., "Molecular Cloning", 133-134, 1982). Ligation can be accomplished with T4 DNA ligase, using a well known type of buffer solution and reaction conditions.
"Transformation" refers to the phenomenon wherein the genotype of a cell (i.e., a host cell) is transformed by the introduction of exogenous genes (DNA) into the said cell. A cell which has undergone such a transformation is known as a "transformant", and is characterized by the capability for replication of the exogenous DNA either as a extranuclear component or in a form integrated into the chromosomes of the said cell.
Next, the method employed for the determina-tion of the DNA sequence of BLase of the present invention will be described in the order of the pro-cesses involved. This DNA sequence was determined by the analysis of the genome DNA of the Bacillus lichen-iformis ATCC No. 14580 using a combination of PCR
analysis, Southern blotting, direct sequencing tech-niques, etc.
(1) PCR analysis of genome DNA sequence A DNA sequence encoding BLase can be ob tained, for example, from genome DNA. In order to obtain the DNA, first, the genome DNA of Bacillus licheniformis ATCC No. 14580 is isolated from cultured cells of the said strain by the conventional technique (M. Stahl et al., J. Bacteriology, 154, 406-412, 1983).
This genome DNA is used as the template DNA for PCR
analysis. The oligonucleotide primers used for PCR are synthesized by conventional methods on the basis of the amino acid sequence in the vicinity of the amino termi-nus of the purified enzyme, determined in Section IV
Item (8) above, and/or the amino acid sequences of the peptides obtained by partial hydrolysis of the said enzyme. For example, the oligonucleotide encoding the amino acid sequence Thr Asn Thr Thr Ala Tyr Pro Tyr which corresponds to the 12th through 19th positions reckoned from the amino terminus of BLase (see Table 3) is used as sense primer BL8 (shown by SEQ ID NO: 2).
This oligonucleotide is a tricosamer which encodes the amino acid sequence upto the second base of the triplet codon for the tyrosine residue of c-terminus.
T T T A
BL8: 5'- AC AACAC AC GCTTACCC TA
C C C G
Separately, another oligonucleotide primer is synthe-sized on the basis of a peptide which is obtained by the decomposition of the purified enzyme with lysylen-dopeptidase followed by sequencing and the sequence of which is most reliable. As described in Example 2 below, the sequence Gly Tyr Pro Gly Asp Lys (SEQ ID
N0: 8) is obtained, hence, the octadecamer complemen-tary to an oligonucleotide encoding this amino acid sequence is used as antisense primer BL83 (shown by SEQ
ID NO: 3).
T A T C T
BL83: 5' - TT TC CC GGATA CC
C G G A G
Then, PCR is performed using the aforesaid genome DNA, the sense primer BL8, and the antisense primer BL83, thereby extending and amplifying the target DNA strands in the genome DNA. The PCR products so obtained are subjected to agarose gel electrophoresis, thereby obtaining a DNA fragment of approximately 370 bp. This DNA fragment is incorporated into a suitable vector, and after subcloning, the base sequence of the fragment is determined by the Sanger technique. The aforesaid amino acid sequence Gly Tyr Pro Gly Asp Lys which constituted the basis for the preparation of the anti-sense primer HL83 was identified as that located in positions 131-136 in the amino acid sequence of BLase.
(2) Southern blotting analysis of genome DNA
The genome DNA derived from the Bacillus licheniformis ATCC No. 14580, prepared in Item (1) above, is digested with the restriction enzyme SalI, and after separation by agarose gel electrophoresis, the DNA fragments so obtained are blotted onto a nylon membrane filter, and analyzed by the Southern tech nique. The probe used for hybridization is the BL8-BL83 PCR product obtained in Item (1) above, labelled with 32P-dCTP by the conventional method. The DNA
fragment which displays positive hybridization to this BL8-BL83 product is recognized as a band corresponding to a length of approximately 3.1 kb.
(3) Sequencing of genome DNA by PCR
The genome DNA of the Bacillus licheniformis ATCC No. 14580, obtained in Item (1) above, is digested with Sall, then this digest is incorporated into a suitable vector, for example, pUC119 vector, and a PCR
is conducted using a portion of the known DNA sequence as a primer. For example, a portion of the DNA se-quence of pUC119 located upstream to the aforesaid genome DNA is used as sense primer RV (shown by SEQ ID
NO: 4), and a DNA sequence complementary to a sequence in the vicinity of the 3' terminus of the 375 by DNA
fragment analyzed in Item (2) above is used as anti-sense primer B125 (shown by SEQ ID NO: 5).
RV: 5' - CAGGAAACAGCTATGAC
B125: 5' - TGTCCCAACAAGTGATGA
A DNA fragment of approximately 1050 by is obtained by the PCR. The base sequence of this fragment can be determined by the direct DNA sequencing method (Gibbs et al., Pro. tdatl. Acad. Sci. U.S.A., 86, 1919-1923, 1989). In this manner, the DNA sequence encoding BLase can be ascertained from the amino terminus up to the middle portion of the sequence.
Next, the portion of the sequence on the 3' side of the genome DNA can be determined by the follow-ing procedure. First, in the same manner as indicated above, the genome DNA of Bacillus licheniformis ATCC
No. 14580 is digested with Sall, and a fragment of approximately 3.1 kb is isolated. This is inserted into M13mp11, and a PCR is conducted. The primers used for this PCR are partial fragments of the 375 by DNA
fragment analyzed in Item (2) above; one is sense primer B40 (shown by SEQ ID NO: 6) which is located upstream to the aforesaid antisense primer B125, and the other is antisense primer M4 (shown by SEQ ID
NO: 7) which has a DNA sequence complementary to a portion of the DNA sequence of M13mp11, and is located downstream to the genome DNA.
H40: 5' - AAAACCGTCGCAACAGCC
M4: 5' - GTTTTCCCAGTCACGAC
The aforesaid PCR yields a DNA fragment of approximate-ly 2.2 kb. The base sequence of this DNA fragment can be determined by the direct DNA sequencing method. In this manner, the base sequence from the 3' terminus to the middle portion of the genome DNA is determined.
The complete DNA sequence of BLase determined in this manner as well as the amino acid sequence determined from this DNA sequence are shown in SEQ ID
N0: 1 and Figure 1. From SEQ ID NO: 1 and Figure 1, it is recognized that the gene encoding the mature protein derived from Bacillus licheniformis contains a DNA
sequence encoding a signal peptide composed of the 94 amino acid residues from N-formylmethionione residue in the -94 position to the lysine residue in the -1 posi-tion, and a DNA sequence encoding the mature protein composed of the 222 amino acid residues from the serine residue in the +1 position to the glutamine residue at the +222 position. Ordinarily, ATG codes for methio-nine, but in this case TTG (fMet) appears to be the translation start codon. In the 332 by segment of the 5' untranslated region starting from the SalI cleavage site, there are a promoter region containing a -35 sequence, a Pribnow box, and a Shine-Dalgarno sequence which is present 9 bases upstream from the aforesaid inferred translation start codon TTG. In the 3' un-translated region, an inverted complementary repeat composed of 13 base pairs is located 8 bases downstream from the stop codon TAA.
VI. Construction of expression vectors As shown in Figure 2, pHY300BLtt, an example of the expression vectors of the present invention, is obtained from the shuttle vector pHY300PLKtt, which contains an alkaline protease terminator derived from Bacillus subtilis ATCC No. 6051, by inserting a DNA
fragment encoding BLase of the present invention shown in SEQ ID NO: 1 (i.e., a DNA fragment containing a promoter, a DNA sequence encoding a signal peptide, a DNA sequence encoding the mature peptide of BLase, and a terminator) into the said vector pHY300PLKtt. As shown in Figure 3, the aforesaid vector pHY300PLKtt is obtained from a vector pHY300PLK which is a shuttle vector of E. coli and B. subtilis, by inserting an alkaline protease terminator derived from Bacillus subtilis ATCC No. 6051 into the vector pHY300PLK.
The aforesaid procedure will now be further explained in the order of the processes involved.
First, as shown in Figure 3, genome DNA is isolated from the Bacillus subtilis ATCC No. 6051 by the method of M. Stahl et al. (supra.), and this is employed as template DNA. Next, a fragment composed of a DNA
sequence corresponding to the vicinity of the 5' termi-nus of the terminator portion of the alkaline protease gene derived from the Bacillus subtilis I-168, with an added XbaI cleavage site, and a fragment complementary to a DNA sequence corresponding to the vicinity of the 3' terminus of the terminator portion, with an added HindIII cleavage site, are synthesized chemically, and a PCR is conducted using these fragments as primers.
The DNA fragment so obtained is then cleaved with XbaI
and HindIII, thereby obtaining a fragment (1) shown in Figure 3. Next, pHY300PLK is cleaved with XbaI and HindIII, thereby obtaining the larger fragment (2) shown in Figure 3. The shuttle vector pHY300PLKtt, containing the alkaline protease terminator derived from Bacillus subtilis ATCC No. 6051, is then con-structed by the ligation of these fragments (1) and (2).
Next, genome DNA is isolated from cultured cells derived from Bacillus licheriiformis ATCC No.
14580 and used as template DNA. Then, a fragment composed of a DNA sequence corresponding to the vicini-ty of the 5' terminus of this template DNA with an added EcoRI cleavage site and a fragment complementary to the DNA sequence corresponding to the 3' terminus of the template DNA with an added XbaI cleavage site are synthesized and used as the sense and antisense prim-ers, respectively. A PCR is conducted using the afore-said template DNA, sense primer, and antisense primer.
Then, the fragment so obtained is cleaved with EcoRI
and XbaI, thereby obtaining a DNA fragment (3) encoding BLase (see Figure 2). This fragment (3) contains a promoter, a DNA sequence encoding a signal peptide, a DNA sequence encoding mature BLase, and a terminator.
Next, the aforesaid vector pHY300PLKtt is cleaved with EcoRI and Xbal, thereby obtaining the larger fragment (4). The expression vector pHY300BLtt of the present invention is then obtained by ligating the aforesaid fragments (3) and (4) (see Figure 2).
This expression vector pHY300BLtt contains, under the control of the BLase promoter, a DNA sequence encoding the signal peptide from the N-formylmethionine residue in the -94 position to the lysine residue in the -1 position; a DNA sequence encoding a mature peptide extending from the serine residue in the +1 position to the glutamine residue in the +222 position of BLase; and a 3' untranslated region comprising a terminator. Still further downstream, the terminator of the alkaline protease derived from Bacillus subtilis ATCC No. 6051 is present.
~ VII. Preparation of transformants and production of BLase The expression vector obtained in Section VI
above is introduced into suitable host cells by a conventional method. For example, the aforesaid vector pHY300BLtt can be introduced into Bacillus subtilis ISW1214 (Takara Shuzo) by the method of J. Spiezen et al. (Pros. Natl. Acad. Sci. U.S.A. 44, 1072, 1958).
The transformant (Bacillus subtilis pHY300BLtt/ISW1214) is cultivated in any medium suitable for the host, thereby producing BLase of the present invention.
Finally, BLase is isolated from the culture broth wherein the transformant has been grown and purified by the process described in Section II above.
EXAMPLES
The present invention will now be further ex-plained with reference to the specific examples.
Example 1 Bacillus licheniformis ATCC No. 14580 was cultivated at 28°C for 36 hours in a medium of pH 7.0 containing 2.0$ of glucose, 2.0$ of soybean meal, 0.25$
of corn steep liquor, 0.5$ of ammonium sulfate, 0.05$
of dipotassium hydrogen phosphate, 0.05% of magnesium sulfate heptahydrate, 0.01$ of ferrous sulfate heptahy-drate, and 0.3% of calcium carbonate. Ninety five liters of the culture broth were filter pressed, and concentrated to approximately 14 liters by means of an ultrafiltration module (Nitto Ultrafiltration Module NTU 2020T P18B (HF); cutoff MW 20,000) and a centrifuge (4200 rpm, 30 minutes). This concentrated cell-free broth was diluted to approximately 28 liters (1.90 ms/cm) with 2 mM calcium chloride. Then the DH.:
of the diluted cell-free broth was adjusted to 6.0 by addition of hydrochloric acid. To this was added .approximately 4 liters of Amberlite CG-50*which had been equilibrated with a 10 mM acetate buffer (pH 6.0) containing 2 mM calcium chloride, and the mixture was agitated for 4 hours at room temperature. After veri-fying that the supernatant had no BLase activity, the supernatant was discarded. Then the Amberlite CG-50 was packed into a 14 x 32 cm glass column. After wash-ing with approximately 10 liters of 10 mM acetate buffer ( pH 6. 0 ) containing 2 mM calcium chloride, elu-tion was performed with 0.5 M sodium acetate buffer (pH 8.5) also containing 2 mM calcium chloride._ The fractions having BLase activity eluted from the Ambwerlite CG-50 were combined (the total volume of the fractions was 2.7 liters) and dialyzed against water for 48 hours. The dialyzate was diluted to 8 liters (2.23 ms/cm) with 2 mM calcium chloride, and after adjustment to pH 6.0, the fluid was adsorbed onto approximately 800 ml of S-Sepharose, packed in a 5 x 40 cm column, which had been equilibrated before-hand with a 5 mM acetate buffer solution (pH 6.0) * trade-mark containing 2 mM calcium chloride. After washing with approximately 5 liters of buffer solution with the same composition as that used for the above-mentioned equil-ibration, the column was subjected to elution with 7 liters of this buffer solution under a linear gradient of 0-0.2 M sodium chloride. The fractions having BLase activity were combined (the total volume of the frac-tions was 900 ml), and dialyzed overnight against a 2 mM aqueous solution of calcium chloride, thereby obtaining approximately 950 ml of dialyzate..
(0.86 ms/cm). The pH of this dialyzate was adjusted to 7.5, then promptly subjected to affinity chromatogra-phy. The carrier used in this affinity chromatography process was approximately 340 ml of CH Sepharose 4B*
. (Phe Leu-D-GluOMe) packed into a 3 x 48 c.~n column, and equilibrated with 5 mM Tris-HC1 (pH 7.5) containing 2 mM calcium chloride. After adsorbing the aforesaid dialyzate in this column, the column was washed with approximately 5 liters of buffer solution with the same composition as that used for equilibration of the column, and then subjected to elution with 3.5 liters of the buffer solution of the same composition under a linear gradient of 0-0.7 M sodium chloride. _ The BLase activity of each fraction so ob-tained was measured by the method for the measurement of enzymatic activit-y shown in Section III of Descrip-tion of the preferred Embodiments. The results are shown in Figure 4. The 280 nm absorbance of each fraction was measured as an index of protein concentra-tion, and the results so obtained are also shown in Figure 4. This figure shows that the BLase was eluted at a concentration of approximately 0.5 M of sodium * trade-mark chloride. The BLase so obtained displayed a single band in SDS-PAGE. In this manner, an 833.1 mg specimen of the said enzyme (quantitated with a Bio Rad protein assay kit), with specific activity of 1.9 x 103 - 2 x 103 U/mg, was obtained from 95 liters of the culture broth. The yield of the enzymatic activity was 27.5.
Example 2 Determination of base sequence of DNA encoding BLase (1) PCR analysis of internal base sequence of genome DNA
One hundred micrograms of the purified BLase obtained in Example 1 which had been treated with DFP
was added in 150 ul of 0.05 M Tris-HC1 (pH 9.0) con-taining 1 M urea, and digested with 1 fag of lysyl endopeptidase (Wako Pure Chemical Industries, Ltd.) at 37°C for 5 hours. The resulting enzyme digest was then isolated and purified by high-performance liquid chromatography using a column packed with TSKgel ODS-120T (4.6 x 250 mm, Tosoh Co. Ltd.) The amino acid sequences of the digested fragments so obtained were investigated with a Model 477A Protein Sequencer (Applied Biosystems), thereby determining the amino acid sequences of five types of fragments. Three of these sequences are indicated below as well as in SEQ
ID NOS: 8, 9, and 10.
Gly-Tyr-Pro-Gly-Asp-Lys (I) Ala-Ile-Val-His-Ile (II) Ser-Thr-Arg-Tyr-Phe-Ile-Pro-Ser (III) Next, genome DNA was isolated from Bacillus lichenifor-mis ATCC No. 14580 by the method of M. Stahl et al.
(supra.), and the DNA was used as a template for PCR
analysis. The oligonucleotide primers used for the PCR
were prepared on the basis of known, portions of the amino acid sequence of the BLase produced by Bacillus licheniformis ATCC No. 14580. First, an oligonucleo-tide encoding the amino acid sequence beginning with the 12th position and terminating with the 19th posi-tion from the amino terminus of the BLase molecule (see Table 3), that is, Thr Asn Thr Thr Ala Tyr Pro Tyr (except that the said oligonucleotide only extends through the second base of the triplet coding for the tyrosine residue at the carboxyl terminal of the oligo-peptide, i.e., the said oligonucleotide is a tricosam-er) was synthesized chemically. This was used as sense primer BL8 (shown by SEQ ID N0: 2).
T T T A
BL8: 5' - AC AACAC AC GCTTACCC TA
C C C G
Next, an octadecamer complimentary to the DNA sequence encoding an amino acid fragment which is a product obtained in the aforesaid lysyl endopeptidase digestion and which has an amino acid sequence with the greatest degree of reliability [i.e., Gly Tyr Pro Gly Asp Lys (shown by SEQ ID NO: 8] was synthesized chemically.
This was used as antisense primer BL83 (shown by SEQ
ID NO: 3).
T A T C T
BL83: 5' - TT TC CC GGATA CC
C G G A G
Using the aforesaid template DNA and oligonu-cleotide primers, the DNA was amplified by the PCR
method (Saiki et al., Science 239, 487-491, 1989). A
portion of the amplified products were analyzed by 1$
agarose gel electrophoresis, thereby confirming the presence of an approximately 370 by DNA fragment. This fragment was isolated and, after blunting.the ends with Klenow fragment, the fragment was cloned in M13mp11 which had been digested with SmaI, and the DNA sequence of the fragment was determined by the Sanger method (Sanger et al., Proc. Natl. Acad. Sci. U.S.A., 74, 5463-5467, 1977). In this manner, the base sequence of a 375 by fragment was determined, and the amino acid sequence corresponding to BL83 was found to be located at positions 131 through 136. Furthermore, the afore-said amino acid sequences (II) and (III) were found to be located at positions 21 through 25 and 79 through 86, respectively.
(2) Southern blotting analysis of genome DNA
The genome DNA derived from Bacillus licheni-formis ATCC No. 14580 obtained by the procedure de-scribed in Item (1) above was digested with the re-striction enzyme SalI, and after separation of the products by 1~ agarose gel electrophoresis, the DNA
fragments were blotted onto a nylon membrane filter and analyzed by the Southern technique. The probe used for the hybridization was the BL8-BL83 PCR product obtained in Item (1) above, and labelled with 32P-dCTP by the conventional method. The DNA fragment which displayed positive hybridization to this BL8-BL83 product was recognized as a band corresponding to a length of approximately 3.1 kb.
(3) Determination of genome DNA sequence by PCR
The genome DNA of Bacillus licheniformis ATCC
No. 14580,- obtained in Item (1) above, was digested with SalI, then the ends of the fragments were blunted with T4 DNA polymerise. This blunt-end fragment was ligated with a dephosphorylated Smal-digested pUC119 vector. This ligation reaction was performed with a commercial kit (Takara Shuzo).
Next, the sense primer RV (shown by SEQ ID
N0: 4) and the antisense primer B125 (shown by SEQ ID
N0: 5), with the base sequences also indicated below, were synthesized chemically and added to an aliquot of the reaction mixture for the aforesaid ligation reac-tion, allowing a PCR reaction to be carried out.
The sense primer RV is a portion of the DNA
sequence of pUC119 and is located upstream to the aforesaid genome DNA, while the antisense primer B125 is a DNA sequence complementary to a sequence in the vicinity of the 3' terminus of the 375 by DNA fragment analyzed in Item (2) above.
RV: 5' - CAGGAAACAGCTATGAC
B125: 5' - TGTCCCAACAAG~1'GATGA
A DNA fragment of approximately 1050 by was obtained by the aforesaid PCR. The base sequence of this fragment was determined by the direct DNA sequencing method (Gibbs et al., Pro. Natl. Acad. Sci. U.S.A., 86, 1919-1923, 1989). In this manner, the DNA sequence encoding the present enzyme was ascertained from the 5' terminus up to the middle portion of the sequence.
The genome DNA of the Bacillus licheniformis ATCC No. 14580, obtained in Item (1) above, was digest-ed with Sall and subjected to 1$ agarose gel electro-phoresis, thereby isolating an approximately 3.1 kb fragment. This fragment was blunt ended with Klenow fragment, and was ligated with dephosphorylated SmaI-digested fragments of M13mp11. Using this as a tem-plate, a PCR was conducted. The primers used for this PCR were sense primer B40 (shown by SEQ ID N0: 6) which is a portion of the 375 by DNA fragment analyzed in Item (2) above (upstream to the aforesaid primer B125), and antisense primer M4 (shown by SEQ ID NO: 7) which is a DNA sequence complementary to a portion of the DNA sequence of M13mp11 located downstream to the genome DNA.
M4: 5' - GTTTTCCCAGTCACGAC
B40: 5' - AAAACCGTCGCAACAGCC
The aforesaid PCR yielded an approximately 2.2 kb DNA
fragment. The base sequence of this DNA fragment was determined by the direct DNA sequencing method. In this manner, the base sequence from the 3' end to the middle portion of the genome DNA was determined.
The complete DNA sequence of BLase determined in this manner as well as the amino acid sequence deduced from the DNA sequence are shown by SEQ ID NO:
1 and Figures 1-1 to 1-3.
The DNA sequence of BLase, as well as DNA
sequences which hybridize to the said DNA sequence are also useful for producing a protease with BLase activi ty which is also within the scope of the present inven tion. The DNA sequence which hybridizes to the DNA
sequence of BLase can be obtained, for example, by the following process.
Various DNA fragments, for example, DNA
fragments derived from various organisms are screened by the use of whole or a part of the DNA sequence of BLase, e.g. a 1124 by DNA fragment which is from A in the 248 position to T in the 1371 position of SEQ ID
NO:1, as a probe. For example, the Southern hybridiza-tion technique (Southern, E. M., J. Mol. Biol. 98, 503-517, 1975) is employed by the use of the 32p-labelled probe, and a hybridization buffer having the following composition.
0.5 M NaH2P04 (pH 7.2) 1 mM EDTA
1$ BSA
7$ SDS
After the hybridization is carried out at 65°C overnight, a filter, to which the probe has been hybridized, is washed 4 times at room temperature with 2 x SSC, 0.1$ SDS, four times each wash being carried out for 10 minutes, at room temperature, thus obtaining a DNA fragment which has about 65% homology with the DNA sequence of HLase. When the filter is washed once for 20 minutes at 50°C, a DNA fragment which has about 80% homology with the DNA sequence of BLase can be ob-tained.
(4) Construction of expression vector (4)-1 Construction of shuttle vector pHY300PLKtt A genome DNA was isolated from Bacillus subtilis ATCC No. 6051 by the method of M. Stahl et al.
(supra.), and this was employed as a template DNA.
Next, as primers, a fragment composed of a DNA sequence corresponding to the vicinity of the 5' terminus of the terminator portion of an alkaline protease gene derived from Bacillus subtilis I-168 (Journal of Bacteriology 158, 411-418, 1984), with an added Xbal cleavage site (sense primer A, shown by SEQ ID NO: 11), and a frag-ment complementary to a DNA sequence corresponding to the vicinity of the 3' terminus of the terminator portion, with an added HindIII cleavage site (antisense primer B, shown by SEQ ID N0: 12), were synthesized chemically.
Sense primer A:
5' - GAGTCTAGAGCAGCTGCACAATAATAG -3' Antisense primer B:
5' - GAGAAGCTTGACAGAGAACAGAGAAG -3' Then, a PCR was conducted using the aforesaid template DNA and these two primers. The DNA fragment so ob-tained was then cleaved with XbaI and HindIII, thereby obtaining fragment (1) shown in Figure 3. Next, the shuttle vector pHY300PLK (Takara Shuzo) was cleaved with XbaI and HindIII, thereby obtaining the larger fragment ( 2 ) ( see Figure 3 ) . A shuttle vector pHY300PLKtt, containing the alkaline protease termina-for derived from Bacillus subtilis ATCC No. 6051, was then constructed by ligation of these fragments (1) and (2).
(4)-2 Construction of expression vector pHY300BLtt A genome DNA was isolated from cultured cells of Bacillus licheniformis ATCC No. 14580 by the method of M. Stahl et al. (supra.) and used as a template DNA.
Then, a single-stranded DNA fragment corresponding to the vicinity of the 5' terminus of this template DNA
with an added EcoRI cleavage site and a single-stranded DNA fragment complementary to a DNA sequence corre-sponding to the 3' terminus of the template DNA with an added Xbal cleavage site were synthesized and used as sense primer C (shown by SEQ ID NO: 13) and antisense primer D (shown by SEQ ID NO: 14), respectively.
Sense primer C:
5'- CAAGAATTCGGCTTCCCGTGCGCCTCC - 3' Antisense primer D:
5'- TTGTCTAGAATTTGCCGATCAGCGGTC - 3' A PCR was conducted using the aforesaid template DNA, sense primer C, and antisense primer D. Then, the fragment so obtained was cleaved with EcoRI and XbaI, thereby obtaining a DNA fragment (3) encoding BLase (see Figure 2). Next, the aforesaid vector pHY300PLKtt was cleaved with EcoRI and Xbal, thereby obtaining the larger fragment (4). The aforesaid fragments (3) and (4) were then ligated with T4 DNA lipase. The ligation mixture was used to transform E, coli K-12 C600. The transformants were cultivated on an agar plate medium containing ampicillin, and the ampillicin-resistant colonies were selected. Then, plasmid DNA was isolated from the cells of the selected colonies, and the inser-tion of the aforesaid DNA fragment (3) in the correct direction was verified from restriction enzyme cleavage patterns.
(5) Preparation of transformants and production of BLase The expression vector pHY300BLtt obtained in Item (4) above was introduced into Bacillus subtilis ISW1214 (Takara Shuzo) by the method of J. Spizien et al. (Proc. Natl. Acad. Sci. U.S.A. 44, 1072 (1958)).
The bacteria were then cultivated on a plated agar medium containing tetracycline, and the tetracycline-resistant colonies were selected, thus obtaining the desired transformant (Bacillus subtilis pHY300BLtt/ISW1214).
The transformant was transplanted to 5 ml of LB medium (10 g trypton, 5 g yeast extract, and 5 g sodium chloride with water added to yield a total volume of 1 liter; pH 7.2) and shake-cultured at 37°C
for 18 hours. Then, 1 ml of this culture broth was added to 10 ml of Sc+ medium which had been sterilized in an autoclave at 120°C for 20 minutes, and shake-cultured was carried out at 28°C.
Composition of Sc+medium Soluble starch lOg Glycerol 5g Bacto soytone 5g CSL 2.5g Yeast extract lg Calcium carbonate 3g Water is added so that the total volume should be 1 L (pH 7.0) The aforesaid culture broth was centrifuged at 2500 x g for 5 minutes, and the supernatant was .obtained. The BLase activity of this supernatant was measured by the method for the measurement of enzymatic activity described in the Description of the Preferred Embodiments. The results of these measurements are shown in Table 4. The quantity of protein per liter of the culture broth was calculated on the basis of an assumed BLase specific activity of 2500 U/mg.
Table 4 Cultivation HLase Protein period (days) activity content (units/ml) (mg/L) 1 15 6.0 2 56 22.4 3 72 28.8 4 79 31.6 5 69 27.6 As described above, the present invention provides a new protease which specifically cleaves the peptide bonds at the carboxyl termini of glutamic acid residues in the amino acid sequences of polypeptides and a method for the preparation of the protease from bacteria of genus Bacillus.
This type of protease can be utilized for a variety of purposes, such as protein analysis and cleavage of the peptide chains of fusion proteins at desired sites, etc.
SEQ ID N0: 1 SEQUENCE TYPE: Nucleotide with corresponding protein SEQUENCE LENGTH: 1448 base pairs STRANDEDNESS: double TOPOLOGY: linear MOLECULE TYPE: genomic DNA
ORIGINAL SOURCE
ORGANISM: Bacillus licheniformis STRAIN: ATCC NO. 14580 FEATURES:
from 323 to 1270 by CDS(E) from 323 to 604 by signal peptide(E) from 605 to 1270 by mature peptide(E) OTHER INFORMATION:
Xaa at -94 position of amino acid sequence: formyl methionine TACATTACCCGGTATCAATA TATGATCAAA CAAAATGTTA ATACACACCT T.TAGTATGAT 240 AAG AAA CGA
GGT
Xaa Val Ser Lys Lys Ser Val Lys Arg Gly -g4 -90 -95 Leu Ile Thr Gly Leu Ile Gly Ile Ser Ile Tyr Ser Leu Gly Met His Pro Ala Gln Ala Ala Pro Ser Pro His Thr Pro Val Ser Ser Asp Pro Ser Tyr Lys Ala Glu Thr Ser Val Thr Tyr Asp Pro Asn Ile Lys Ser Asp Gln Tyr Gly Leu Tyr Ser Lys Ala Phe Thr Gly Thr Gly Lys Val -45 ~ -40 -35 Asn Glu Thr Lys Glu Lys Ala Glu Lys Lys Ser Pro Ala Lys Ala Pro Tyr Ser Ile Lys Ser Val Ile Gly Ser Asp Asp Arg Thr Arg Val Thr Asn Thr Thr Ala Tyr Pro Tyr Arg Ala Ile Val His Ile Ser Ser Ser Ile Gly Ser Cys Thr Gly Trp Met Ile Gly Pro Lys Thr Val Ala Thr Ala Gly His Cys Ile Tyr Asp Thr Ser Ser Gly Ser Phe Ala Gly Thr 45 50 ~ 55 60 Ala Thr Val Ser Pro Gly Arg Asn Gly Thr Ser Tyr Pro Tyr Gly Ser Val Lys Ser Thr Arg Tyr Phe Ile Pro Ser Gly Trp Arg Ser Gly Asn Thr Asn Tyr Asp Tyr Gly Ala Ile Glu Leu Ser Glu Pro Ile Gly Asn Thr Val Gly Tyr Phe Gly Tyr Ser Tyr Thr Thr Ser Ser Leu Val Gly Thr Thr Val Thr Ile Ser Gly Tyr Pro Gly Asp Lys Thr Ala Gly Thr Gln Trp Gln His Ser Gly Pro Ile Ala Ile Ser Glu Thr Tyr Lys Leu Gln Tyr Ala Met Asp Thr Tyr Gly Gly Gln Ser Gly Ser Pro Val Phe Glu Gln Ser Ser Ser Arg Thr Asn Cys Ser Gly Pro Cys Ser Leu Ala Val His Thr Asn Gly Val Tyr Gly Gly Ser Ser Tyr Asn Arg Gly Thr Arg Ile Thr Lys Glu Val Phe Asp Asn Leu Thr Asn Trp Lys Asn Ser Ala Gln SEQ ID N0: 2 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 23 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid, Synthetic DNA
SEQ ID NO: 3 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 18 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid, Synthetic DNA
YTTRTCKCCM GGATAKCC lg SEQ ID N0: 4 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 17 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid, Synthetic DNA
CAGGAAACAG CTATGAC
SEQ ID N0: 5 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 18 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid, Synthetic DNA
TGTCCCAACA AGTGATGA lg SEQ ID NO: 6 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 18 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid, Synthetic DNA
AAAACCGTCG CAACAGCC lg SEQ ID N0: 7 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 17 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid, Synthetic DNA
GTTTTCCCAG TCACGAC 1~
SEQ ID NO: 8 SEQUENCE TYPE: amino acid SEQUENCE LENGTH: 6 amino acids TOPOLOGY: linear MOLECULE TYPE: peptide FRAGMENT TYPE: internal fragment ORIGINAL SOURCE
ORGANISM: Bacillus licheniformis STRAIN: ATCC No. 14580 Gly Tyr Pro Gly Asp Lys SEQ ID N0: 9 SEQUENCE TYPE: amino acid SEQUENCE LENGTH: 5 amino acids TOPOLOGY: linear MOLECULE TYPE: peptide FRAGMENT TYPE: internal fragment ORIGINAL SOURCE:
ORGANISM: Bacillus licheniformis STRAIN: ATCC No. 14580 Ala Ile Val His Ile SEQ ID N0: 10 SEQUENCE TYPE: amino acid SEQUENCE LENGTH: 8 amino acids TOPOLOGY: linear MOLECULE TYPE: peptide FRAGMENT TYPE: internal fragment ORIGINAL SOURCE:
ORGANISM: Bacillus licheniformis STRAIN: ATCC No. 14580 Ser Thr Arg Tyr Phe Ile Pro Ser SEQ ID NO: 11 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 27 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid,Synthetic DNA
SEQ ID N0: 12 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 26 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid,Synthetic DNA
SEQ ID N0: 13 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 27 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid,Synthetic DNA
SEQ ID N0: 14 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 27 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid,Synthetic DNA
I. Culture conditions No special medium is required for the culti vation of the aforesaid bacterial strain, and any of the various conventional types of culture medium are suitable for this purpose. For example, a medium con-taining glucose, soybean powder, meat extract, corn steep liquor, and the various inorganic salts, etc., can be used. The appropriate medium pH is 5-9, prefer-ably approximately 7.0, the appropriate medium tempera-ture is 15-50°C, preferably approximately 28°C, and the bacteria are cultured, for example, aerobically with stirring or shaking for approximately 36 hours. The enzyme BLase of the present invention was principally secreted extracellularly.
II. Collection of enzyme Known processes for the collection and puri fication of enzymes can be used, either singly or in combination, for the collection and purification of the present enzyme from the aforesaid culture broth. For example, the culture broth can be subjected to filter pressing, ultrafiltration, and centrifugal separation, thereby obtaining a cell-free liquid concentrate. The enzyme of the present invention can then be obtained from this concentrate by an appropriate method of purification. For example, the aforesaid concentrate can be subjected first to preliminary purification by - g -ion exchange chromatography, and then to chromatography with S-Sepharose, and finally to affinity chromato-graphy, thereby obtaining the present enzyme. In Example 1 shown below, enzyme specimen with activity 1.9 x 103 to 2.4 x 103 U/mg (assayed by the method for the measurement of enzymatic activity described below) was obtained by this type of procedure. This enzyme specimen was used for the determination of enzyme properties described below.
III. Method for the measurement of enzymatic activity Z-Phe Leu Glu-pNA (wherein Z is a carbo-benzoxy group and pNA is a p-nitroaniline group), used as a substrate, is dissolved in 50 mM Tris-HC1 (pH 7.5, containing 2 mM calcium chloride and 2$ DMF) so as to achieve a final substrate concentration of 0.2 mM. An enzyme solution is added to this mixture, and a reac-tion is conducted at 37°C for 10 minutes, then the 410 nm absorbance of the p-nitroaniline released into the liquid by the enzymatic reaction is measured. The enzymatic activity present when this absorbance is 1.0 is defined as 1 unit (U).
IV. Enzyme properties The enzymatic properties and protein chemical properties of BLase of the present invention are as follows.
(1) Enzymatic action and substrate specificity (i) The synthetic substrates shows in Table 1 were prepared, and each of them was dissolved in 50 ml Tris-HC1 (pH 7.5, containing 2 mM calcium chloride and dimethylformamide (DMF) or dimethyl sulfoxide (DMSO) in _ g _ the proportions indicated by Table 1) so as to achieve the concentration shown in Table 1. Then, the present enzyme was added to this solution and a reaction was conducted at 25°C. The 410 nm absorbance of the p-nitroaniline released into the liquid by the enzyma-tic reaction was measured, and the quantity (nmol) of p-nitroaniline released from 1 mg of the substrate per minute was calculated; the results so obtained are shown in Table 1.
c .
. _.
c -- E
Q: c \
Ui c3 N O O O O O O O
C.C
e-~ C
E
CD G O O ' C O O O O
C
QJ . N
....
_ C E
I c I
Q.~' c p ~
~ t_ ~
-+~ O O O C J O 0 0 ( O
o~
cC '-~ N N .-~ .-.a,--1.--, .-v ~ L.
~~C
C C Vj Q: ~
U4-O p C O C -. L. LL '.-.L. Vj ',- C-O ~ ' ~ ~ ,.s ~
U ' p p D C~ C ~ C
s' C~
.~~
-~ E
c -s Q7 c~ L.'7 L~J
U t-. O O O O .-t -C' O O O
c .~.~
C cn O O N N O O ~-t --s C: ..O
c ci-.
. _. p + .~ a- + .r a. t .t .z.
d d d d d d -~ d d a:
z ~ ~. z z z z z a. c, c. .:. c, c. Q. :..,c.
a. _ Q .~ c. ~:..~, ~. ~ .
, _.
+= --r C!) ~- V; ~ ~.. ~; --~ Q: C
cts O d C~ d E- C C/: d .. c~
~
._.
-i' ~ - ~, c~ t-, U: C1: Q: :: ~,; N N -- ---~ _.. .._ -~ d CC C.~ CC d .
~ _.
--tC~: Q7 Q: ~ I
_ ~ ~ sw Ci ~ ~ Q
..D N N U -C
' C
i (ii) Oxidized insulin B chain was selected as a protein substrate, and the actions of the present enzyme and V8 protease derived from Staphylococcus aureus upon this substrate were compared by the follow-s ing procedure. First, oxidized insulin B chain was dissolved in 50 mM ammonium bicarbonate (pH 7.8), the present enzyme or the aforesaid V8 protease was added so as to achieve an enzyme/substrate ratio of 1/100 (W/W), and a reaction was conducted over a prescribed period of time. The reaction mixture was then sub-jected to HPLC using a 4.6 x 250 mm column packed with Vydac Protein C4 (300 angstroms), which was eluted under a 0-50~ acetonitrile linear gradient in 0.1$ TFA, raising the acetonitrile concentration by 1.67~/min.
Peptide mapping revealed that, when either of the enzymes was used, the peptide bonds at the carboxyl termini of the glutamic acid residues were cleaved, and the products of enzymatic hydrolysis induced by the two enzymes were identical with each other.
Thus, the results of the aforesaid analyses (i) and (ii) demonstrated that the present enzyme cleaves peptide bonds at the carboxyl termini of glu tamic acid residues, and is indeed a glutamic acid specific endopeptidase.
(2) Optimal pH and stable pH range Z-Phe Leu Glu-pNA as a substrate was dis solved in 50 mM Tris-HC1 containing 10$ DMF and 2 mM
calcium chloride. Then, the present enzyme was added to this mixture, a reaction was conducted for 15 minutes at 37°C, and the 410 nm absorbance of the p-nitroaniline released into the liquid by the enzymat-is reaction was measured. The aforesaid reaction was conducted at various pH values, and the results re-vealed that the optimal pH for enzymatic activity is 8Ø
Next, the present enzyme was maintained at 25°C for 24 hours at various pH values, and in each case the enzyme after this treatment was allowed to react with a substrate in accordance with the proce-dures described in the method for the measurement of enzymatic activity mentioned above. The results indi-cate that the stable pH range of the present enzyme is about 4.0-10Ø In a pH range of 6.5-8.5, the enzymat-ic activity is maintained at 100$, and in pH ranges ex-ceeding 4.0 up to less than 6.5, and exceeding 8.5 up to 10.0, the enzymatic activity is maintained at 80-100$.
(3) Thermal stability The present enzyme was maintained for 15 minutes at various temperatures in a buffer solution containing 2 mM calcium chloride at pH 7.8. In each case, the enzyme after this treatment was allowed to react with a substrate in accordance with the proce-dures described in the method for the measurement of enzymatic activity mentioned above. The results indicated that under the aforesaid conditions the present enzyme is stable at temperatures up to 60°C.
When the present enzyme was similarly kept in solutions not containing calcium chloride, it was stable at tem-peratures up to 50°C.
(4) Effect of inhibitors The present enzyme is completely inhibited by diisopropyl fluorophosphate (DFP). This fact indicates that the present enzyme is classified as a serine pro s tease.
The present enzyme is also completely inhib ited by Z-Phe Leu Glu CH2C1. This fact indicates that the present enzyme is a glutamic acid specific endo peptidase.
The present enzyme is partially inhibited by EDTA, with a maximum inhibition ratio of approximately 72$. This inhibitory effect of EDTA is completely nullified by the addition of metal ions at low concen-trations (10-4 to 10-3 M of calcium or magnesium ions, etc.).
The aforesaid facts indicate that the present enzyme is a typical serine protease, the stability of which is related to the presence of metal ions.
(5) Molecular weight The molecular weight of the present enzyme was determined by SDS-PAGE using 15$ gel (1.0 mm) and RainbowTM Protein Molecular Weight Marker (Amersham), and was calculated to be 26,000. The molecular weight was also calculated from the amino acid sequence deter mined on the basis of the gene sequencing analysis to be described below, and the value so obtained was 23,567 which is somewhat different from the aforesaid value obtained by SDS-PAGE. Nevertheless, the results of the various protein chemical analyses to be de-scribed below (amino acid composition, amino terminal sequences, amino acid composition in the vicinity of the carboxyl terminus) agreed well with the structure deduced from the DNA sequence. This indicates that the molecular weight obtained by SDS-PAGE was, in fact, slightly in excess of the true value.
(6) Isoelectric point Investigation of the isoelectric point of the present enzyme using the Pharmacia FAST System (Pharma lite, pH 3.0-10.0) yielded values above pH,9.0, and a normal value could not be obtained.
(7) Amino acid composition Using 4 M methanesulfonic acid (containing 0.2$ of 3-(2-aminoethyl)indole), the present enzyme was hydrolyzed at 110°C for prescribed time intervals (24, 48, or 72 hours). The respective hydrolysates were then subjected to amino acid analysis using a Hitachi Model 835 amino acid analyzer. The results of this analysis, corrected for the decomposition of amino acids in the process of hydrolysis, are shown in Table 2. The amino acid composition calculated from the DNA
sequence of the present enzyme (described below) are also shown for comparison in Table 2. The two sets of results clearly display good agreement.
cC C-Ir---41.C7CCD.---iCCDCv.~.L''COL~CCL'~OL~-> r-iC'~~."~L'7C'~'OOO~~O~G~7C0.'.VL~-~CO~G~
~O 0.~.Nr'C"~".'C"~JLOriLJJL~~7L'--CV:.Vr--~'C'r-1C7 N ,--a .--i ,.-.~ G~
c U
O
..-.. td .--' U
. r, O ' n E
O
U
U
..-. .-.
. r 00 ~ O7 G~ C r-1 ~G' Q~ 'J'J C~'J r---i U . ~''~ "~' L~- ~ C C'rJ r-I L~-c,~.
c~ ~ CJCO~'~C'L'CDCUGCCCCC~'JOC'rJL'L~-.---i~O
O 'C7 ~ ri cYJ L'J ~f' CYJ ttJ r-1 CD C O
CD G~l L'- CV ~7 .--1 '~ r-i C U '-1 r-I r-~ C
. .., E a d ~
U
.
r, U
C7 cd \
r--~ 0.. t. t-, ~ O ~ c~ CIA ,-.-~ .u U cd = t-, Q: C!i U7 CG G, ...CO Cn ..C N r--' t-, ,.- .- ~ c-,! Q: .~
~--~ U ~ .~ 7~ -- s~ L.
c-,-c.C d~--C/aC~~C~dU~~.--.fir-~.~sdE-- C
.
E
d (8) Partial amino acid sequences (i) Amino acid sequence near N terminus A Model 477A Protein Sequencer (Applied Biosystems) was used to analyze the amino acid sequence of the present enzyme in the vicinity of the amino terminus. The enzyme samples used were inhibited beforehand with DFP. The amino acid sequence from the amino terminus to the 23rd residue is shown in Table 3.
c~
.'.V ~J '~T~ L~J '~~~~ L~ r-1 per" 'C' 4'7 C-C a°
U ''-~ C' V O .-~ r--~ GV CV L''W'.V C'rJ 'C" C~l d7 L''~C''J~'JLt7CD'C'c'ri~GVG~7 G~
O 'n C ~ ~ G ~.. t-. cd ~. C 4.. C,p cL N ~
. .-. V V; ..c . ; ~--~ ~, t-. ~, t~ .-.-~ ,-.-.
E c~ d F- r- d E-- G.., E-. d d .-- ~
d C
O
cd Q
"',.~. G7 C'~J ~ LCD CD L~ x7 O~ O r--~ CV C~'J
cd .+~ r--~ r-~ ~ ~-i r-i r-~-i r-i ~ GV N N
by O
D
O
>~ r~CDCD~VCONr-iGYJoO:DCYJ'c'' O
U~ ~'Lt'Jr-SOC~7riy'Jr-I~LrJL'JCO
U CV o~ o~ ~ Gw7 l.n L~ Cf~ CrJ t-c~ :D ;'rJ
O "O
C ~ ~--~ t-, ,--~ QJ ~ L-. CL G. ta0 L-~ t~0 r-~ l-, ' ~' U d7 c~ .-. r-. N Cn (n L-. .G t-.. cd .C
~ cd c/~ ~- ~-~ C~ c/~ d d d E- d ~- E--d c O
. ....
U ~C U
cd .:._.y--( ~ C~r-r -c,'i L'~ C.O L~- 00 C3~ O ~--t '~7 f-. Cn r-i r-i r-1 c~ b0 U
C
(ii) Amino acid sequence near C terminus Carbvxypeptidase A (CPase A) or carboxypepti-dase Y (CPase Y) was allowed to act upon samples of the present enzyme inhibited beforehand with DFP, and the quantities of amino acids released by these reactions were measured with an amino acid analyzer of Hitachi Model 835. However, the amino acid sequence in the vicinity of the carboxyl terminus of the present enzyme could not be accurately determined using either of the aforesaid carboxypeptidases. Nevertheless, the presence of glutamine, serine, alanine and asparagine in the vicinity of the carboxyl terminus was verified.
V. Determination of DNA secruence encoding BLase Certain terminology employed in the specifi-cation of the present invention is defined as follows.
"Oligonucleotide" refers to a short single-strand DNA molecule. Oligonucleotides can be chemical-ly synthesized in accordance with known methods.
Unless otherwise stated, the oligonucleotides used in the processes of the present invention are chemically synthesized, and are purified by gel chromatography using Sephadex G50*and high-performance liquid chroma-tography (HPLC) with a reverse phase silica gel column.
"PCR" is an acronym of "polymerase chain reaction", and refers to a method for enzvmatic amDli-fication of a definite DNA region (Saiki et al., Science, 239, 487-497, 1988). First, the DNA to be amplified is converted to single-strand form by thermal denaturation, and oligonucleotide primers (two types, i.e., sense and antisense strands, each having a com-* trade-mark plemental sequence to the 3'-terminal region of the said single-stranded DNA) are annealed to the regions at the respective 3'-termini of the single-stranded DNA
(i.e., the template DNA). Next, the extension of the DNA strands from the respective primers is accomplished by a reaction using DNA polymerise. By repeating this sequence of reactions, the target DNA can be amplified by a factor of 100,000 to 1,000,000.
"Southern blotting" is a method for determin-ing whether or not a specified gene is contained in a DNA fragment obtained by cleavage with a certain re-striction enzyme. Southern blotting is performed by first digesting the DNA sample under investigation with a restriction enzyme which specifically recognizes a certain base sequence in duplex DNA and cleaves this DNA at specific sites. The digest so obtained is subjected to 1$ agarose gel electrophoresis, then denatured into single-stranded DNA by alkali treatment, and transferred to a nylon filter. Separately, an oligonucleotide or DNA fragment constituting a portion of the gene in question is prepared and labelled to obtain a probe. Hybridization of the single-stranded DNA on the nylon filter with this probe is then used to detect the presence of the gene in question.
"Ligation" refers to the creation of phospho-diester bond between two duplex DNA fragments. In this technique, in order to prevent the self-ligation of the duplex DNA fragments, one of the fragments is subjected to prior dephosphorylation treatment by the convention-al method (T. Maniatis et al., "Molecular Cloning", 133-134, 1982). Ligation can be accomplished with T4 DNA ligase, using a well known type of buffer solution and reaction conditions.
"Transformation" refers to the phenomenon wherein the genotype of a cell (i.e., a host cell) is transformed by the introduction of exogenous genes (DNA) into the said cell. A cell which has undergone such a transformation is known as a "transformant", and is characterized by the capability for replication of the exogenous DNA either as a extranuclear component or in a form integrated into the chromosomes of the said cell.
Next, the method employed for the determina-tion of the DNA sequence of BLase of the present invention will be described in the order of the pro-cesses involved. This DNA sequence was determined by the analysis of the genome DNA of the Bacillus lichen-iformis ATCC No. 14580 using a combination of PCR
analysis, Southern blotting, direct sequencing tech-niques, etc.
(1) PCR analysis of genome DNA sequence A DNA sequence encoding BLase can be ob tained, for example, from genome DNA. In order to obtain the DNA, first, the genome DNA of Bacillus licheniformis ATCC No. 14580 is isolated from cultured cells of the said strain by the conventional technique (M. Stahl et al., J. Bacteriology, 154, 406-412, 1983).
This genome DNA is used as the template DNA for PCR
analysis. The oligonucleotide primers used for PCR are synthesized by conventional methods on the basis of the amino acid sequence in the vicinity of the amino termi-nus of the purified enzyme, determined in Section IV
Item (8) above, and/or the amino acid sequences of the peptides obtained by partial hydrolysis of the said enzyme. For example, the oligonucleotide encoding the amino acid sequence Thr Asn Thr Thr Ala Tyr Pro Tyr which corresponds to the 12th through 19th positions reckoned from the amino terminus of BLase (see Table 3) is used as sense primer BL8 (shown by SEQ ID NO: 2).
This oligonucleotide is a tricosamer which encodes the amino acid sequence upto the second base of the triplet codon for the tyrosine residue of c-terminus.
T T T A
BL8: 5'- AC AACAC AC GCTTACCC TA
C C C G
Separately, another oligonucleotide primer is synthe-sized on the basis of a peptide which is obtained by the decomposition of the purified enzyme with lysylen-dopeptidase followed by sequencing and the sequence of which is most reliable. As described in Example 2 below, the sequence Gly Tyr Pro Gly Asp Lys (SEQ ID
N0: 8) is obtained, hence, the octadecamer complemen-tary to an oligonucleotide encoding this amino acid sequence is used as antisense primer BL83 (shown by SEQ
ID NO: 3).
T A T C T
BL83: 5' - TT TC CC GGATA CC
C G G A G
Then, PCR is performed using the aforesaid genome DNA, the sense primer BL8, and the antisense primer BL83, thereby extending and amplifying the target DNA strands in the genome DNA. The PCR products so obtained are subjected to agarose gel electrophoresis, thereby obtaining a DNA fragment of approximately 370 bp. This DNA fragment is incorporated into a suitable vector, and after subcloning, the base sequence of the fragment is determined by the Sanger technique. The aforesaid amino acid sequence Gly Tyr Pro Gly Asp Lys which constituted the basis for the preparation of the anti-sense primer HL83 was identified as that located in positions 131-136 in the amino acid sequence of BLase.
(2) Southern blotting analysis of genome DNA
The genome DNA derived from the Bacillus licheniformis ATCC No. 14580, prepared in Item (1) above, is digested with the restriction enzyme SalI, and after separation by agarose gel electrophoresis, the DNA fragments so obtained are blotted onto a nylon membrane filter, and analyzed by the Southern tech nique. The probe used for hybridization is the BL8-BL83 PCR product obtained in Item (1) above, labelled with 32P-dCTP by the conventional method. The DNA
fragment which displays positive hybridization to this BL8-BL83 product is recognized as a band corresponding to a length of approximately 3.1 kb.
(3) Sequencing of genome DNA by PCR
The genome DNA of the Bacillus licheniformis ATCC No. 14580, obtained in Item (1) above, is digested with Sall, then this digest is incorporated into a suitable vector, for example, pUC119 vector, and a PCR
is conducted using a portion of the known DNA sequence as a primer. For example, a portion of the DNA se-quence of pUC119 located upstream to the aforesaid genome DNA is used as sense primer RV (shown by SEQ ID
NO: 4), and a DNA sequence complementary to a sequence in the vicinity of the 3' terminus of the 375 by DNA
fragment analyzed in Item (2) above is used as anti-sense primer B125 (shown by SEQ ID NO: 5).
RV: 5' - CAGGAAACAGCTATGAC
B125: 5' - TGTCCCAACAAGTGATGA
A DNA fragment of approximately 1050 by is obtained by the PCR. The base sequence of this fragment can be determined by the direct DNA sequencing method (Gibbs et al., Pro. tdatl. Acad. Sci. U.S.A., 86, 1919-1923, 1989). In this manner, the DNA sequence encoding BLase can be ascertained from the amino terminus up to the middle portion of the sequence.
Next, the portion of the sequence on the 3' side of the genome DNA can be determined by the follow-ing procedure. First, in the same manner as indicated above, the genome DNA of Bacillus licheniformis ATCC
No. 14580 is digested with Sall, and a fragment of approximately 3.1 kb is isolated. This is inserted into M13mp11, and a PCR is conducted. The primers used for this PCR are partial fragments of the 375 by DNA
fragment analyzed in Item (2) above; one is sense primer B40 (shown by SEQ ID NO: 6) which is located upstream to the aforesaid antisense primer B125, and the other is antisense primer M4 (shown by SEQ ID
NO: 7) which has a DNA sequence complementary to a portion of the DNA sequence of M13mp11, and is located downstream to the genome DNA.
H40: 5' - AAAACCGTCGCAACAGCC
M4: 5' - GTTTTCCCAGTCACGAC
The aforesaid PCR yields a DNA fragment of approximate-ly 2.2 kb. The base sequence of this DNA fragment can be determined by the direct DNA sequencing method. In this manner, the base sequence from the 3' terminus to the middle portion of the genome DNA is determined.
The complete DNA sequence of BLase determined in this manner as well as the amino acid sequence determined from this DNA sequence are shown in SEQ ID
N0: 1 and Figure 1. From SEQ ID NO: 1 and Figure 1, it is recognized that the gene encoding the mature protein derived from Bacillus licheniformis contains a DNA
sequence encoding a signal peptide composed of the 94 amino acid residues from N-formylmethionione residue in the -94 position to the lysine residue in the -1 posi-tion, and a DNA sequence encoding the mature protein composed of the 222 amino acid residues from the serine residue in the +1 position to the glutamine residue at the +222 position. Ordinarily, ATG codes for methio-nine, but in this case TTG (fMet) appears to be the translation start codon. In the 332 by segment of the 5' untranslated region starting from the SalI cleavage site, there are a promoter region containing a -35 sequence, a Pribnow box, and a Shine-Dalgarno sequence which is present 9 bases upstream from the aforesaid inferred translation start codon TTG. In the 3' un-translated region, an inverted complementary repeat composed of 13 base pairs is located 8 bases downstream from the stop codon TAA.
VI. Construction of expression vectors As shown in Figure 2, pHY300BLtt, an example of the expression vectors of the present invention, is obtained from the shuttle vector pHY300PLKtt, which contains an alkaline protease terminator derived from Bacillus subtilis ATCC No. 6051, by inserting a DNA
fragment encoding BLase of the present invention shown in SEQ ID NO: 1 (i.e., a DNA fragment containing a promoter, a DNA sequence encoding a signal peptide, a DNA sequence encoding the mature peptide of BLase, and a terminator) into the said vector pHY300PLKtt. As shown in Figure 3, the aforesaid vector pHY300PLKtt is obtained from a vector pHY300PLK which is a shuttle vector of E. coli and B. subtilis, by inserting an alkaline protease terminator derived from Bacillus subtilis ATCC No. 6051 into the vector pHY300PLK.
The aforesaid procedure will now be further explained in the order of the processes involved.
First, as shown in Figure 3, genome DNA is isolated from the Bacillus subtilis ATCC No. 6051 by the method of M. Stahl et al. (supra.), and this is employed as template DNA. Next, a fragment composed of a DNA
sequence corresponding to the vicinity of the 5' termi-nus of the terminator portion of the alkaline protease gene derived from the Bacillus subtilis I-168, with an added XbaI cleavage site, and a fragment complementary to a DNA sequence corresponding to the vicinity of the 3' terminus of the terminator portion, with an added HindIII cleavage site, are synthesized chemically, and a PCR is conducted using these fragments as primers.
The DNA fragment so obtained is then cleaved with XbaI
and HindIII, thereby obtaining a fragment (1) shown in Figure 3. Next, pHY300PLK is cleaved with XbaI and HindIII, thereby obtaining the larger fragment (2) shown in Figure 3. The shuttle vector pHY300PLKtt, containing the alkaline protease terminator derived from Bacillus subtilis ATCC No. 6051, is then con-structed by the ligation of these fragments (1) and (2).
Next, genome DNA is isolated from cultured cells derived from Bacillus licheriiformis ATCC No.
14580 and used as template DNA. Then, a fragment composed of a DNA sequence corresponding to the vicini-ty of the 5' terminus of this template DNA with an added EcoRI cleavage site and a fragment complementary to the DNA sequence corresponding to the 3' terminus of the template DNA with an added XbaI cleavage site are synthesized and used as the sense and antisense prim-ers, respectively. A PCR is conducted using the afore-said template DNA, sense primer, and antisense primer.
Then, the fragment so obtained is cleaved with EcoRI
and XbaI, thereby obtaining a DNA fragment (3) encoding BLase (see Figure 2). This fragment (3) contains a promoter, a DNA sequence encoding a signal peptide, a DNA sequence encoding mature BLase, and a terminator.
Next, the aforesaid vector pHY300PLKtt is cleaved with EcoRI and Xbal, thereby obtaining the larger fragment (4). The expression vector pHY300BLtt of the present invention is then obtained by ligating the aforesaid fragments (3) and (4) (see Figure 2).
This expression vector pHY300BLtt contains, under the control of the BLase promoter, a DNA sequence encoding the signal peptide from the N-formylmethionine residue in the -94 position to the lysine residue in the -1 position; a DNA sequence encoding a mature peptide extending from the serine residue in the +1 position to the glutamine residue in the +222 position of BLase; and a 3' untranslated region comprising a terminator. Still further downstream, the terminator of the alkaline protease derived from Bacillus subtilis ATCC No. 6051 is present.
~ VII. Preparation of transformants and production of BLase The expression vector obtained in Section VI
above is introduced into suitable host cells by a conventional method. For example, the aforesaid vector pHY300BLtt can be introduced into Bacillus subtilis ISW1214 (Takara Shuzo) by the method of J. Spiezen et al. (Pros. Natl. Acad. Sci. U.S.A. 44, 1072, 1958).
The transformant (Bacillus subtilis pHY300BLtt/ISW1214) is cultivated in any medium suitable for the host, thereby producing BLase of the present invention.
Finally, BLase is isolated from the culture broth wherein the transformant has been grown and purified by the process described in Section II above.
EXAMPLES
The present invention will now be further ex-plained with reference to the specific examples.
Example 1 Bacillus licheniformis ATCC No. 14580 was cultivated at 28°C for 36 hours in a medium of pH 7.0 containing 2.0$ of glucose, 2.0$ of soybean meal, 0.25$
of corn steep liquor, 0.5$ of ammonium sulfate, 0.05$
of dipotassium hydrogen phosphate, 0.05% of magnesium sulfate heptahydrate, 0.01$ of ferrous sulfate heptahy-drate, and 0.3% of calcium carbonate. Ninety five liters of the culture broth were filter pressed, and concentrated to approximately 14 liters by means of an ultrafiltration module (Nitto Ultrafiltration Module NTU 2020T P18B (HF); cutoff MW 20,000) and a centrifuge (4200 rpm, 30 minutes). This concentrated cell-free broth was diluted to approximately 28 liters (1.90 ms/cm) with 2 mM calcium chloride. Then the DH.:
of the diluted cell-free broth was adjusted to 6.0 by addition of hydrochloric acid. To this was added .approximately 4 liters of Amberlite CG-50*which had been equilibrated with a 10 mM acetate buffer (pH 6.0) containing 2 mM calcium chloride, and the mixture was agitated for 4 hours at room temperature. After veri-fying that the supernatant had no BLase activity, the supernatant was discarded. Then the Amberlite CG-50 was packed into a 14 x 32 cm glass column. After wash-ing with approximately 10 liters of 10 mM acetate buffer ( pH 6. 0 ) containing 2 mM calcium chloride, elu-tion was performed with 0.5 M sodium acetate buffer (pH 8.5) also containing 2 mM calcium chloride._ The fractions having BLase activity eluted from the Ambwerlite CG-50 were combined (the total volume of the fractions was 2.7 liters) and dialyzed against water for 48 hours. The dialyzate was diluted to 8 liters (2.23 ms/cm) with 2 mM calcium chloride, and after adjustment to pH 6.0, the fluid was adsorbed onto approximately 800 ml of S-Sepharose, packed in a 5 x 40 cm column, which had been equilibrated before-hand with a 5 mM acetate buffer solution (pH 6.0) * trade-mark containing 2 mM calcium chloride. After washing with approximately 5 liters of buffer solution with the same composition as that used for the above-mentioned equil-ibration, the column was subjected to elution with 7 liters of this buffer solution under a linear gradient of 0-0.2 M sodium chloride. The fractions having BLase activity were combined (the total volume of the frac-tions was 900 ml), and dialyzed overnight against a 2 mM aqueous solution of calcium chloride, thereby obtaining approximately 950 ml of dialyzate..
(0.86 ms/cm). The pH of this dialyzate was adjusted to 7.5, then promptly subjected to affinity chromatogra-phy. The carrier used in this affinity chromatography process was approximately 340 ml of CH Sepharose 4B*
. (Phe Leu-D-GluOMe) packed into a 3 x 48 c.~n column, and equilibrated with 5 mM Tris-HC1 (pH 7.5) containing 2 mM calcium chloride. After adsorbing the aforesaid dialyzate in this column, the column was washed with approximately 5 liters of buffer solution with the same composition as that used for equilibration of the column, and then subjected to elution with 3.5 liters of the buffer solution of the same composition under a linear gradient of 0-0.7 M sodium chloride. _ The BLase activity of each fraction so ob-tained was measured by the method for the measurement of enzymatic activit-y shown in Section III of Descrip-tion of the preferred Embodiments. The results are shown in Figure 4. The 280 nm absorbance of each fraction was measured as an index of protein concentra-tion, and the results so obtained are also shown in Figure 4. This figure shows that the BLase was eluted at a concentration of approximately 0.5 M of sodium * trade-mark chloride. The BLase so obtained displayed a single band in SDS-PAGE. In this manner, an 833.1 mg specimen of the said enzyme (quantitated with a Bio Rad protein assay kit), with specific activity of 1.9 x 103 - 2 x 103 U/mg, was obtained from 95 liters of the culture broth. The yield of the enzymatic activity was 27.5.
Example 2 Determination of base sequence of DNA encoding BLase (1) PCR analysis of internal base sequence of genome DNA
One hundred micrograms of the purified BLase obtained in Example 1 which had been treated with DFP
was added in 150 ul of 0.05 M Tris-HC1 (pH 9.0) con-taining 1 M urea, and digested with 1 fag of lysyl endopeptidase (Wako Pure Chemical Industries, Ltd.) at 37°C for 5 hours. The resulting enzyme digest was then isolated and purified by high-performance liquid chromatography using a column packed with TSKgel ODS-120T (4.6 x 250 mm, Tosoh Co. Ltd.) The amino acid sequences of the digested fragments so obtained were investigated with a Model 477A Protein Sequencer (Applied Biosystems), thereby determining the amino acid sequences of five types of fragments. Three of these sequences are indicated below as well as in SEQ
ID NOS: 8, 9, and 10.
Gly-Tyr-Pro-Gly-Asp-Lys (I) Ala-Ile-Val-His-Ile (II) Ser-Thr-Arg-Tyr-Phe-Ile-Pro-Ser (III) Next, genome DNA was isolated from Bacillus lichenifor-mis ATCC No. 14580 by the method of M. Stahl et al.
(supra.), and the DNA was used as a template for PCR
analysis. The oligonucleotide primers used for the PCR
were prepared on the basis of known, portions of the amino acid sequence of the BLase produced by Bacillus licheniformis ATCC No. 14580. First, an oligonucleo-tide encoding the amino acid sequence beginning with the 12th position and terminating with the 19th posi-tion from the amino terminus of the BLase molecule (see Table 3), that is, Thr Asn Thr Thr Ala Tyr Pro Tyr (except that the said oligonucleotide only extends through the second base of the triplet coding for the tyrosine residue at the carboxyl terminal of the oligo-peptide, i.e., the said oligonucleotide is a tricosam-er) was synthesized chemically. This was used as sense primer BL8 (shown by SEQ ID N0: 2).
T T T A
BL8: 5' - AC AACAC AC GCTTACCC TA
C C C G
Next, an octadecamer complimentary to the DNA sequence encoding an amino acid fragment which is a product obtained in the aforesaid lysyl endopeptidase digestion and which has an amino acid sequence with the greatest degree of reliability [i.e., Gly Tyr Pro Gly Asp Lys (shown by SEQ ID NO: 8] was synthesized chemically.
This was used as antisense primer BL83 (shown by SEQ
ID NO: 3).
T A T C T
BL83: 5' - TT TC CC GGATA CC
C G G A G
Using the aforesaid template DNA and oligonu-cleotide primers, the DNA was amplified by the PCR
method (Saiki et al., Science 239, 487-491, 1989). A
portion of the amplified products were analyzed by 1$
agarose gel electrophoresis, thereby confirming the presence of an approximately 370 by DNA fragment. This fragment was isolated and, after blunting.the ends with Klenow fragment, the fragment was cloned in M13mp11 which had been digested with SmaI, and the DNA sequence of the fragment was determined by the Sanger method (Sanger et al., Proc. Natl. Acad. Sci. U.S.A., 74, 5463-5467, 1977). In this manner, the base sequence of a 375 by fragment was determined, and the amino acid sequence corresponding to BL83 was found to be located at positions 131 through 136. Furthermore, the afore-said amino acid sequences (II) and (III) were found to be located at positions 21 through 25 and 79 through 86, respectively.
(2) Southern blotting analysis of genome DNA
The genome DNA derived from Bacillus licheni-formis ATCC No. 14580 obtained by the procedure de-scribed in Item (1) above was digested with the re-striction enzyme SalI, and after separation of the products by 1~ agarose gel electrophoresis, the DNA
fragments were blotted onto a nylon membrane filter and analyzed by the Southern technique. The probe used for the hybridization was the BL8-BL83 PCR product obtained in Item (1) above, and labelled with 32P-dCTP by the conventional method. The DNA fragment which displayed positive hybridization to this BL8-BL83 product was recognized as a band corresponding to a length of approximately 3.1 kb.
(3) Determination of genome DNA sequence by PCR
The genome DNA of Bacillus licheniformis ATCC
No. 14580,- obtained in Item (1) above, was digested with SalI, then the ends of the fragments were blunted with T4 DNA polymerise. This blunt-end fragment was ligated with a dephosphorylated Smal-digested pUC119 vector. This ligation reaction was performed with a commercial kit (Takara Shuzo).
Next, the sense primer RV (shown by SEQ ID
N0: 4) and the antisense primer B125 (shown by SEQ ID
N0: 5), with the base sequences also indicated below, were synthesized chemically and added to an aliquot of the reaction mixture for the aforesaid ligation reac-tion, allowing a PCR reaction to be carried out.
The sense primer RV is a portion of the DNA
sequence of pUC119 and is located upstream to the aforesaid genome DNA, while the antisense primer B125 is a DNA sequence complementary to a sequence in the vicinity of the 3' terminus of the 375 by DNA fragment analyzed in Item (2) above.
RV: 5' - CAGGAAACAGCTATGAC
B125: 5' - TGTCCCAACAAG~1'GATGA
A DNA fragment of approximately 1050 by was obtained by the aforesaid PCR. The base sequence of this fragment was determined by the direct DNA sequencing method (Gibbs et al., Pro. Natl. Acad. Sci. U.S.A., 86, 1919-1923, 1989). In this manner, the DNA sequence encoding the present enzyme was ascertained from the 5' terminus up to the middle portion of the sequence.
The genome DNA of the Bacillus licheniformis ATCC No. 14580, obtained in Item (1) above, was digest-ed with Sall and subjected to 1$ agarose gel electro-phoresis, thereby isolating an approximately 3.1 kb fragment. This fragment was blunt ended with Klenow fragment, and was ligated with dephosphorylated SmaI-digested fragments of M13mp11. Using this as a tem-plate, a PCR was conducted. The primers used for this PCR were sense primer B40 (shown by SEQ ID N0: 6) which is a portion of the 375 by DNA fragment analyzed in Item (2) above (upstream to the aforesaid primer B125), and antisense primer M4 (shown by SEQ ID NO: 7) which is a DNA sequence complementary to a portion of the DNA sequence of M13mp11 located downstream to the genome DNA.
M4: 5' - GTTTTCCCAGTCACGAC
B40: 5' - AAAACCGTCGCAACAGCC
The aforesaid PCR yielded an approximately 2.2 kb DNA
fragment. The base sequence of this DNA fragment was determined by the direct DNA sequencing method. In this manner, the base sequence from the 3' end to the middle portion of the genome DNA was determined.
The complete DNA sequence of BLase determined in this manner as well as the amino acid sequence deduced from the DNA sequence are shown by SEQ ID NO:
1 and Figures 1-1 to 1-3.
The DNA sequence of BLase, as well as DNA
sequences which hybridize to the said DNA sequence are also useful for producing a protease with BLase activi ty which is also within the scope of the present inven tion. The DNA sequence which hybridizes to the DNA
sequence of BLase can be obtained, for example, by the following process.
Various DNA fragments, for example, DNA
fragments derived from various organisms are screened by the use of whole or a part of the DNA sequence of BLase, e.g. a 1124 by DNA fragment which is from A in the 248 position to T in the 1371 position of SEQ ID
NO:1, as a probe. For example, the Southern hybridiza-tion technique (Southern, E. M., J. Mol. Biol. 98, 503-517, 1975) is employed by the use of the 32p-labelled probe, and a hybridization buffer having the following composition.
0.5 M NaH2P04 (pH 7.2) 1 mM EDTA
1$ BSA
7$ SDS
After the hybridization is carried out at 65°C overnight, a filter, to which the probe has been hybridized, is washed 4 times at room temperature with 2 x SSC, 0.1$ SDS, four times each wash being carried out for 10 minutes, at room temperature, thus obtaining a DNA fragment which has about 65% homology with the DNA sequence of HLase. When the filter is washed once for 20 minutes at 50°C, a DNA fragment which has about 80% homology with the DNA sequence of BLase can be ob-tained.
(4) Construction of expression vector (4)-1 Construction of shuttle vector pHY300PLKtt A genome DNA was isolated from Bacillus subtilis ATCC No. 6051 by the method of M. Stahl et al.
(supra.), and this was employed as a template DNA.
Next, as primers, a fragment composed of a DNA sequence corresponding to the vicinity of the 5' terminus of the terminator portion of an alkaline protease gene derived from Bacillus subtilis I-168 (Journal of Bacteriology 158, 411-418, 1984), with an added Xbal cleavage site (sense primer A, shown by SEQ ID NO: 11), and a frag-ment complementary to a DNA sequence corresponding to the vicinity of the 3' terminus of the terminator portion, with an added HindIII cleavage site (antisense primer B, shown by SEQ ID N0: 12), were synthesized chemically.
Sense primer A:
5' - GAGTCTAGAGCAGCTGCACAATAATAG -3' Antisense primer B:
5' - GAGAAGCTTGACAGAGAACAGAGAAG -3' Then, a PCR was conducted using the aforesaid template DNA and these two primers. The DNA fragment so ob-tained was then cleaved with XbaI and HindIII, thereby obtaining fragment (1) shown in Figure 3. Next, the shuttle vector pHY300PLK (Takara Shuzo) was cleaved with XbaI and HindIII, thereby obtaining the larger fragment ( 2 ) ( see Figure 3 ) . A shuttle vector pHY300PLKtt, containing the alkaline protease termina-for derived from Bacillus subtilis ATCC No. 6051, was then constructed by ligation of these fragments (1) and (2).
(4)-2 Construction of expression vector pHY300BLtt A genome DNA was isolated from cultured cells of Bacillus licheniformis ATCC No. 14580 by the method of M. Stahl et al. (supra.) and used as a template DNA.
Then, a single-stranded DNA fragment corresponding to the vicinity of the 5' terminus of this template DNA
with an added EcoRI cleavage site and a single-stranded DNA fragment complementary to a DNA sequence corre-sponding to the 3' terminus of the template DNA with an added Xbal cleavage site were synthesized and used as sense primer C (shown by SEQ ID NO: 13) and antisense primer D (shown by SEQ ID NO: 14), respectively.
Sense primer C:
5'- CAAGAATTCGGCTTCCCGTGCGCCTCC - 3' Antisense primer D:
5'- TTGTCTAGAATTTGCCGATCAGCGGTC - 3' A PCR was conducted using the aforesaid template DNA, sense primer C, and antisense primer D. Then, the fragment so obtained was cleaved with EcoRI and XbaI, thereby obtaining a DNA fragment (3) encoding BLase (see Figure 2). Next, the aforesaid vector pHY300PLKtt was cleaved with EcoRI and Xbal, thereby obtaining the larger fragment (4). The aforesaid fragments (3) and (4) were then ligated with T4 DNA lipase. The ligation mixture was used to transform E, coli K-12 C600. The transformants were cultivated on an agar plate medium containing ampicillin, and the ampillicin-resistant colonies were selected. Then, plasmid DNA was isolated from the cells of the selected colonies, and the inser-tion of the aforesaid DNA fragment (3) in the correct direction was verified from restriction enzyme cleavage patterns.
(5) Preparation of transformants and production of BLase The expression vector pHY300BLtt obtained in Item (4) above was introduced into Bacillus subtilis ISW1214 (Takara Shuzo) by the method of J. Spizien et al. (Proc. Natl. Acad. Sci. U.S.A. 44, 1072 (1958)).
The bacteria were then cultivated on a plated agar medium containing tetracycline, and the tetracycline-resistant colonies were selected, thus obtaining the desired transformant (Bacillus subtilis pHY300BLtt/ISW1214).
The transformant was transplanted to 5 ml of LB medium (10 g trypton, 5 g yeast extract, and 5 g sodium chloride with water added to yield a total volume of 1 liter; pH 7.2) and shake-cultured at 37°C
for 18 hours. Then, 1 ml of this culture broth was added to 10 ml of Sc+ medium which had been sterilized in an autoclave at 120°C for 20 minutes, and shake-cultured was carried out at 28°C.
Composition of Sc+medium Soluble starch lOg Glycerol 5g Bacto soytone 5g CSL 2.5g Yeast extract lg Calcium carbonate 3g Water is added so that the total volume should be 1 L (pH 7.0) The aforesaid culture broth was centrifuged at 2500 x g for 5 minutes, and the supernatant was .obtained. The BLase activity of this supernatant was measured by the method for the measurement of enzymatic activity described in the Description of the Preferred Embodiments. The results of these measurements are shown in Table 4. The quantity of protein per liter of the culture broth was calculated on the basis of an assumed BLase specific activity of 2500 U/mg.
Table 4 Cultivation HLase Protein period (days) activity content (units/ml) (mg/L) 1 15 6.0 2 56 22.4 3 72 28.8 4 79 31.6 5 69 27.6 As described above, the present invention provides a new protease which specifically cleaves the peptide bonds at the carboxyl termini of glutamic acid residues in the amino acid sequences of polypeptides and a method for the preparation of the protease from bacteria of genus Bacillus.
This type of protease can be utilized for a variety of purposes, such as protein analysis and cleavage of the peptide chains of fusion proteins at desired sites, etc.
SEQ ID N0: 1 SEQUENCE TYPE: Nucleotide with corresponding protein SEQUENCE LENGTH: 1448 base pairs STRANDEDNESS: double TOPOLOGY: linear MOLECULE TYPE: genomic DNA
ORIGINAL SOURCE
ORGANISM: Bacillus licheniformis STRAIN: ATCC NO. 14580 FEATURES:
from 323 to 1270 by CDS(E) from 323 to 604 by signal peptide(E) from 605 to 1270 by mature peptide(E) OTHER INFORMATION:
Xaa at -94 position of amino acid sequence: formyl methionine TACATTACCCGGTATCAATA TATGATCAAA CAAAATGTTA ATACACACCT T.TAGTATGAT 240 AAG AAA CGA
GGT
Xaa Val Ser Lys Lys Ser Val Lys Arg Gly -g4 -90 -95 Leu Ile Thr Gly Leu Ile Gly Ile Ser Ile Tyr Ser Leu Gly Met His Pro Ala Gln Ala Ala Pro Ser Pro His Thr Pro Val Ser Ser Asp Pro Ser Tyr Lys Ala Glu Thr Ser Val Thr Tyr Asp Pro Asn Ile Lys Ser Asp Gln Tyr Gly Leu Tyr Ser Lys Ala Phe Thr Gly Thr Gly Lys Val -45 ~ -40 -35 Asn Glu Thr Lys Glu Lys Ala Glu Lys Lys Ser Pro Ala Lys Ala Pro Tyr Ser Ile Lys Ser Val Ile Gly Ser Asp Asp Arg Thr Arg Val Thr Asn Thr Thr Ala Tyr Pro Tyr Arg Ala Ile Val His Ile Ser Ser Ser Ile Gly Ser Cys Thr Gly Trp Met Ile Gly Pro Lys Thr Val Ala Thr Ala Gly His Cys Ile Tyr Asp Thr Ser Ser Gly Ser Phe Ala Gly Thr 45 50 ~ 55 60 Ala Thr Val Ser Pro Gly Arg Asn Gly Thr Ser Tyr Pro Tyr Gly Ser Val Lys Ser Thr Arg Tyr Phe Ile Pro Ser Gly Trp Arg Ser Gly Asn Thr Asn Tyr Asp Tyr Gly Ala Ile Glu Leu Ser Glu Pro Ile Gly Asn Thr Val Gly Tyr Phe Gly Tyr Ser Tyr Thr Thr Ser Ser Leu Val Gly Thr Thr Val Thr Ile Ser Gly Tyr Pro Gly Asp Lys Thr Ala Gly Thr Gln Trp Gln His Ser Gly Pro Ile Ala Ile Ser Glu Thr Tyr Lys Leu Gln Tyr Ala Met Asp Thr Tyr Gly Gly Gln Ser Gly Ser Pro Val Phe Glu Gln Ser Ser Ser Arg Thr Asn Cys Ser Gly Pro Cys Ser Leu Ala Val His Thr Asn Gly Val Tyr Gly Gly Ser Ser Tyr Asn Arg Gly Thr Arg Ile Thr Lys Glu Val Phe Asp Asn Leu Thr Asn Trp Lys Asn Ser Ala Gln SEQ ID N0: 2 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 23 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid, Synthetic DNA
SEQ ID NO: 3 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 18 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid, Synthetic DNA
YTTRTCKCCM GGATAKCC lg SEQ ID N0: 4 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 17 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid, Synthetic DNA
CAGGAAACAG CTATGAC
SEQ ID N0: 5 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 18 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid, Synthetic DNA
TGTCCCAACA AGTGATGA lg SEQ ID NO: 6 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 18 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid, Synthetic DNA
AAAACCGTCG CAACAGCC lg SEQ ID N0: 7 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 17 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid, Synthetic DNA
GTTTTCCCAG TCACGAC 1~
SEQ ID NO: 8 SEQUENCE TYPE: amino acid SEQUENCE LENGTH: 6 amino acids TOPOLOGY: linear MOLECULE TYPE: peptide FRAGMENT TYPE: internal fragment ORIGINAL SOURCE
ORGANISM: Bacillus licheniformis STRAIN: ATCC No. 14580 Gly Tyr Pro Gly Asp Lys SEQ ID N0: 9 SEQUENCE TYPE: amino acid SEQUENCE LENGTH: 5 amino acids TOPOLOGY: linear MOLECULE TYPE: peptide FRAGMENT TYPE: internal fragment ORIGINAL SOURCE:
ORGANISM: Bacillus licheniformis STRAIN: ATCC No. 14580 Ala Ile Val His Ile SEQ ID N0: 10 SEQUENCE TYPE: amino acid SEQUENCE LENGTH: 8 amino acids TOPOLOGY: linear MOLECULE TYPE: peptide FRAGMENT TYPE: internal fragment ORIGINAL SOURCE:
ORGANISM: Bacillus licheniformis STRAIN: ATCC No. 14580 Ser Thr Arg Tyr Phe Ile Pro Ser SEQ ID NO: 11 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 27 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid,Synthetic DNA
SEQ ID N0: 12 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 26 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid,Synthetic DNA
SEQ ID N0: 13 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 27 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid,Synthetic DNA
SEQ ID N0: 14 SEQUENCE TYPE: nucleic acid SEQUENCE LENGTH: 27 base pairs STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: Other nucleic acid,Synthetic DNA
Claims (6)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A purified and isolated protease, which cleaves the peptide bonds at the carboxyl termini of glutamic acid residues in polypeptides, and which contains an amino acid sequence from serine in the +1 position to glutamine in the +222 position of SEQ ID NO: 1.
2. A protease of claim 1, which is derived from Bacillus licheniformis.
3. A protease of claim 2, derived from Bacillus licheniformis ATCC No. 14580.
4. A protease of claim 1, 2 or 3, which has the following properties:
(1) Optimal pH: 8.0, and (2) Stable pH range: pH 6.5-8.5 at 25°C.
(1) Optimal pH: 8.0, and (2) Stable pH range: pH 6.5-8.5 at 25°C.
5. A protease of any one of claims 1 to 4, wherein the protease is produced by cultivating a transformant containing a DNA sequence encoding the amino acid sequence from serine in the +1 position to glutamine in the +222 position of SEQ ID NO: 1.
6. A purified and isolated protease of claim 1, wherein said protease is:
(1) classified as a serine protease to be inhibited by diisopropyl fluorophosphate;
and (2) its enzymatic activity is maintained at 80-100% in a pH
range of from 4.0 to 10Ø
(1) classified as a serine protease to be inhibited by diisopropyl fluorophosphate;
and (2) its enzymatic activity is maintained at 80-100% in a pH
range of from 4.0 to 10Ø
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2288110A JP3046344B2 (en) | 1990-10-24 | 1990-10-24 | New protease |
JP2-288110 | 1990-10-24 | ||
CA002054030A CA2054030C (en) | 1990-10-24 | 1991-10-23 | Protease from bacillus licheniformis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002054030A Division CA2054030C (en) | 1990-10-24 | 1991-10-23 | Protease from bacillus licheniformis |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2281956A1 CA2281956A1 (en) | 1992-04-25 |
CA2281956C true CA2281956C (en) | 2001-12-11 |
Family
ID=17725933
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002054030A Expired - Lifetime CA2054030C (en) | 1990-10-24 | 1991-10-23 | Protease from bacillus licheniformis |
CA002281956A Expired - Lifetime CA2281956C (en) | 1990-10-24 | 1991-10-23 | A novel protease |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002054030A Expired - Lifetime CA2054030C (en) | 1990-10-24 | 1991-10-23 | Protease from bacillus licheniformis |
Country Status (21)
Country | Link |
---|---|
US (1) | US5459064A (en) |
EP (1) | EP0482879B2 (en) |
JP (1) | JP3046344B2 (en) |
KR (1) | KR0174271B1 (en) |
CN (2) | CN1068047C (en) |
AT (1) | ATE132194T1 (en) |
AU (1) | AU632002B2 (en) |
BR (1) | BR9104613A (en) |
CA (2) | CA2054030C (en) |
DE (1) | DE69115843T3 (en) |
DK (1) | DK0482879T4 (en) |
ES (1) | ES2081442T5 (en) |
FI (1) | FI915004A0 (en) |
GR (1) | GR3019035T3 (en) |
HU (1) | HU913333D0 (en) |
IE (1) | IE913714A1 (en) |
IL (1) | IL99820A0 (en) |
NO (1) | NO914158D0 (en) |
NZ (1) | NZ240305A (en) |
PT (1) | PT99322B (en) |
TW (1) | TW242165B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5863573A (en) * | 1990-03-09 | 1999-01-26 | Novo Nordisk A/S | Process for producing cheese |
JP3153237B2 (en) * | 1990-03-09 | 2001-04-03 | ノボ ノルディスク アクティーゼルスカブ | Protein hydrolyzate |
US7217554B2 (en) | 1999-08-31 | 2007-05-15 | Novozymes A/S | Proteases and variants thereof |
NZ531394A (en) | 1999-08-31 | 2005-10-28 | Novozymes As | Residual protease II (RPII) and variants thereof useful in detergent compositions |
US6558939B1 (en) | 1999-08-31 | 2003-05-06 | Novozymes, A/S | Proteases and variants thereof |
US6727277B1 (en) | 2002-11-12 | 2004-04-27 | Kansas State University Research Foundation | Compounds affecting cholesterol absorption |
CN102250861A (en) | 2004-02-13 | 2011-11-23 | 诺维信公司 | Protease variants |
WO2005123915A1 (en) | 2004-06-21 | 2005-12-29 | Novozymes A/S | Stably maintained multiple copies of at least two orf in the same orientation |
CN101594785B (en) * | 2006-12-20 | 2014-01-08 | 杜邦营养生物科学有限公司 | Milk protein hydrolyzates with reduced immunogenic potential |
CN101215538B (en) * | 2007-12-29 | 2010-06-16 | 北京欣博阳科技有限公司 | Bacillus licheniformis and application thereof |
CN101215537B (en) * | 2007-12-29 | 2010-06-16 | 北京欣博阳科技有限公司 | Bacillus licheniformis and application thereof |
JP2012513771A (en) | 2008-12-31 | 2012-06-21 | ソレイ リミテッド ライアビリティ カンパニー | Proteolytic composition with enhanced CCK release capacity |
CN102387711A (en) | 2008-12-31 | 2012-03-21 | 索莱有限责任公司 | Protein hydrolysate compositions |
EP2585618B1 (en) * | 2010-06-22 | 2014-04-23 | Novozymes A/S | Enzyme dehairing of skins and hides |
CN103561589A (en) | 2011-02-23 | 2014-02-05 | 索莱有限责任公司 | Protein hydrolysate compositions having enhanced CCK and GLP-1 releasing activity |
CN111778231A (en) * | 2020-07-29 | 2020-10-16 | 珠海冀百康生物科技有限公司 | Purification method of lysyl endopeptidase |
WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2966911D1 (en) * | 1978-07-04 | 1984-05-24 | Novo Industri As | Microbial protease preparation suitable for admixture to washing compositions and process for preparing it |
JPS6112287A (en) * | 1984-06-26 | 1986-01-20 | Lion Corp | Recombinant dna, its preparation, bacterial strain containing same, preparation of exocytic secretion enzyme using same, and dna for promoting secretion of exocytic enzyme |
JP2637532B2 (en) * | 1987-02-27 | 1997-08-06 | ギスト ブロカデス ナームローゼ フェンノートチャップ | Stable gene amplification in chromosomal DNA of prokaryotic microorganisms |
PT86864B (en) * | 1987-02-27 | 1992-05-29 | Gist Brocades Nv | PROCESS FOR MOLECULAR CLONING AND EXPRESSION OF GENES ENCODING FOR PROTEOLITIC ENZYMES |
-
1990
- 1990-10-24 JP JP2288110A patent/JP3046344B2/en not_active Expired - Lifetime
-
1991
- 1991-10-18 AU AU86004/91A patent/AU632002B2/en not_active Expired
- 1991-10-22 NZ NZ240305A patent/NZ240305A/en not_active IP Right Cessation
- 1991-10-22 ES ES91309737T patent/ES2081442T5/en not_active Expired - Lifetime
- 1991-10-22 EP EP91309737A patent/EP0482879B2/en not_active Expired - Lifetime
- 1991-10-22 DE DE1991615843 patent/DE69115843T3/en not_active Expired - Lifetime
- 1991-10-22 DK DK91309737T patent/DK0482879T4/en active
- 1991-10-22 AT AT91309737T patent/ATE132194T1/en not_active IP Right Cessation
- 1991-10-22 IL IL99820A patent/IL99820A0/en unknown
- 1991-10-22 HU HU913333A patent/HU913333D0/en unknown
- 1991-10-23 FI FI915004A patent/FI915004A0/en unknown
- 1991-10-23 IE IE371491A patent/IE913714A1/en not_active Application Discontinuation
- 1991-10-23 NO NO91914158A patent/NO914158D0/en unknown
- 1991-10-23 CA CA002054030A patent/CA2054030C/en not_active Expired - Lifetime
- 1991-10-23 CA CA002281956A patent/CA2281956C/en not_active Expired - Lifetime
- 1991-10-24 KR KR1019910018708A patent/KR0174271B1/en not_active IP Right Cessation
- 1991-10-24 TW TW080108399A patent/TW242165B/zh not_active IP Right Cessation
- 1991-10-24 CN CN91111128A patent/CN1068047C/en not_active Expired - Lifetime
- 1991-10-24 BR BR919104613A patent/BR9104613A/en unknown
- 1991-10-24 PT PT99322A patent/PT99322B/en not_active IP Right Cessation
-
1993
- 1993-03-23 US US08/035,634 patent/US5459064A/en not_active Expired - Lifetime
-
1996
- 1996-02-21 GR GR960400438T patent/GR3019035T3/en unknown
-
2000
- 2000-08-19 CN CNB001262483A patent/CN1152955C/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2281956C (en) | A novel protease | |
Kakudo et al. | Purification, characterization, cloning, and expression of a glutamic acid-specific protease from Bacillus licheniformis ATCC 14580. | |
US7449320B2 (en) | Truncated forms of pullulanase | |
US5204254A (en) | Maltopentaose producing amylases | |
JP3396033B2 (en) | New protease | |
Pundle et al. | Bacillus sphaericus penicillin V acylase: Purification, substrate specificity, and active-site characterization | |
Mizukami et al. | Efficient production of thermostable Clostridium thermosulfurogenes β-amylase by Bacillus brevis | |
JP2003274964A (en) | New glucose dehydrogenase and gene encoding the same | |
JPH0670765A (en) | Protease, gene coding the same, method for producing the protease and its use | |
JP2001292772A (en) | Nitrile hydratase gene and amidase gene derived from bacterium belonging to the genus rhodococcus | |
Oyama et al. | Purification and characterization of an alkaline proteinase produced by Pimelobacter sp. Z-483 | |
JP4561021B2 (en) | 5-substituted hydantoin racemase, DNA encoding the same, recombinant DNA, transformed cell, and method for producing optically active amino acid | |
US7618800B2 (en) | Glycerol kinase, which has high resistance against preservative | |
JPH07107980A (en) | Production of mold protein disulfide isomerase in high efficiency | |
JP4058514B2 (en) | Cathepsin C-like enzyme and method for producing the same | |
JP2003210176A (en) | 5-substituted hydantoin racemase, dna encoding the same, recombinant dna, transformed cell and method for producing optically active amino acid | |
JPH05244957A (en) | Acidic protease gene having insusceptibility to pepstatin derived from bacterium of genus pseudomonas | |
JP2003210177A (en) | 5-substituted hydantoin racemase, dna encoding the same, recombinant dna, transformed cell and method for producing optically active amino acid | |
JPH09154574A (en) | New creatinine amidohydrolase | |
JPH11318454A (en) | Gene encoding proline dipeptidase | |
JPH07170976A (en) | Novel enzyme having n-methylvaline oxidase | |
WO1998006832A1 (en) | Protopectinase | |
JPH07184649A (en) | New proteinase, production of the same enzyme, gene coding the same enzyme and variant enzyme of the same enzyme | |
JPH04211370A (en) | New protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |